Identification

Name
Acetylsalicylic acid
Accession Number
DB00945  (APRD00264, EXPT00475)
Type
Small Molecule
Groups
Approved, Vet approved
Description

The prototypical analgesic used in the treatment of mild to moderate pain. It has anti-inflammatory and antipyretic properties and acts as an inhibitor of cyclooxygenase which results in the inhibition of the biosynthesis of prostaglandins. Acetylsalicylic acid also inhibits platelet aggregation and is used in the prevention of arterial and venous thrombosis. (From Martindale, The Extra Pharmacopoeia, 30th ed, p5)

Structure
Thumb
Synonyms
  • 2-Acetoxybenzenecarboxylic acid
  • 2-Acetoxybenzoic acid
  • Acetylsalicylate
  • Acetylsalicylsäure
  • acide 2-(acétyloxy)benzoïque
  • acide acétylsalicylique
  • ácido acetilsalicílico
  • Acidum acetylsalicylicum
  • ASA
  • Aspirin
  • Azetylsalizylsäure
  • o-acetoxybenzoic acid
  • O-acetylsalicylic acid
  • o-carboxyphenyl acetate
  • Polopiryna
  • salicylic acid acetate
External IDs
BAY1019036 / NSC-27223 / NSC-406186
Product Images
Prescription Products
NameDosageStrengthRouteLabellerMarketing StartMarketing End
DurlazaCapsule, extended release162.5 mg/1OralNew Haven Pharmaceuticals, Inc.2015-09-16Not applicableUs
Generic Prescription Products
NameDosageStrengthRouteLabellerMarketing StartMarketing End
Clopidogrel KitKitCambridge Therapeutics Technologies, Llc2017-07-01Not applicableUs
Over the Counter Products
NameDosageStrengthRouteLabellerMarketing StartMarketing End
7 Select Adult Chewable AspirinTablet, chewable81 mg/1Oral7 Eleven2014-08-052018-03-29Us
7 Select AspirinTablet325 mg/1Oral7 Eleven2014-08-05Not applicableUs
A.S.A.Tablet325 mgOralD.C. Labs Limited2001-05-282005-07-19Canada
A.S.A.Tablet500 mgOralD.C. Labs Limited2001-12-222005-07-19Canada
A.S.A. (acetylsalicylic Acid) Tab 325mg USPTablet325 mgOralAccurex Health Care Manufacturing Inc.1996-12-312003-01-28Canada
A.S.A. 325 Mg TabletTablet325 mgOralJamp Pharma Corporation2003-10-16Not applicableCanada
A.S.A. 80mg Acetylsalicylic Acid TabletsTablet80 mgOralStanley Pharmaceuticals, A Division Of Vita Health Products Inc.1995-12-312002-07-31Canada
A.S.A. Enteric Coated Tab 325mgTablet, delayed release325 mgOralStanley Pharmaceuticals, A Division Of Vita Health Products Inc.1987-12-312004-07-26Canada
A.S.A. Enteric Coated Tab 650mgTablet, delayed release650 mgOralStanley Pharmaceuticals, A Division Of Vita Health Products Inc.1987-12-312004-07-26Canada
A.S.A. Tablets 5gr BPTablet325 mgOralWestcan Pharmaceuticals Ltd.1997-09-081998-04-07Canada
Mixture Products
NameIngredientsDosageRouteLabellerMarketing StartMarketing End
10 Person ANSIAcetylsalicylic acid + Acetaminophen + Bacitracin zinc + Benzalkonium chloride + Benzocaine + Ethanol + Ibuprofen + Lidocaine + Neomycin sulfate + Polymyxin B Sulfate + WaterKitGenuine First Aid2010-04-24Not applicableUs
217Acetylsalicylic acid (325 mg) + Caffeine citrate (30 mg)TabletOralMerck Frosst Canada & Cie, Merck Frosst Canada & Co.1910-12-311998-04-21Canada
217 Strong TabAcetylsalicylic acid (500 mg) + Caffeine citrate (30 mg)TabletOralMerck Frosst Canada & Cie, Merck Frosst Canada & Co.1973-12-311998-04-21Canada
222 TabletsAcetylsalicylic acid (375 mg) + Caffeine citrate (30 mg) + Codeine phosphate (8 mg)TabletOralMcneil Consumer Healthcare Division Of Johnson & Johnson Inc1951-12-312015-08-17Canada
25 Person ANSIAcetylsalicylic acid + Acetaminophen + Bacitracin zinc + Benzalkonium chloride + Benzocaine + Ethanol + Ibuprofen + Isopropyl Alcohol + Lidocaine + Neomycin sulfate + Polymyxin B Sulfate + WaterKitGenuine First Aid2010-04-25Not applicableUs
282 Mep TabAcetylsalicylic acid (350 mg) + Caffeine citrate (30 mg) + Codeine phosphate (15 mg) + Meprobamate (200 mg)TabletOralMerck Frosst Canada & Cie, Merck Frosst Canada & Co.1959-12-311998-08-14Canada
282 TabAcetylsalicylic acid (375 mg) + Caffeine citrate (30 mg) + Codeine phosphate (15 mg)TabletOralMerck Frosst Canada & Cie, Merck Frosst Canada & Co.1951-12-311998-04-21Canada
282 TabletsAcetylsalicylic acid (375 mg) + Caffeine citrate (30 mg) + Codeine phosphate (15 mg)TabletOralPendopharm Division Of De Pharmascience Inc1998-11-01Not applicableCanada
292 TabAcetylsalicylic acid (375 mg) + Caffeine citrate (30 mg) + Codeine phosphate (30 mg)TabletOralMerck Frosst Canada & Cie, Merck Frosst Canada & Co.1951-12-311998-08-14Canada
292 TabletsAcetylsalicylic acid (375 mg) + Caffeine citrate (30 mg) + Codeine phosphate (30 mg)TabletOralPendopharm Division Of De Pharmascience Inc1998-10-01Not applicableCanada
Unapproved/Other Products
NameIngredientsDosageRouteLabellerMarketing StartMarketing End
AspirinAcetylsalicylic acid (81 mg/1)Tablet, chewableOralCardinal Health2011-05-232018-07-31Us
AspirinAcetylsalicylic acid (81 mg/1)Tablet, chewableOralMc Kesson Contract Packaging2011-11-172018-03-08Us
AspirinAcetylsalicylic acid (325 mg/1)TabletOralCardinal Health2011-06-02Not applicableUs
Childrens AspirinAcetylsalicylic acid (81 mg/1)Tablet, chewableOralCardinal Helath2011-06-02Not applicableUs
Enteric AspirinAcetylsalicylic acid (81 mg/1)TabletOralCardinal Health2011-06-022017-07-18Us
Micro-Coated AspirinAcetylsalicylic acid (325 mg/1)TabletOralMc Kesson Contract Packaging2011-09-302018-04-07Us
International/Other Brands
Acenterine / Acetophen (Merck) / Adiro / Aspergum / Aspro / Bayer Aspirin (Bayer HealthCare LLC.) / Easprin / Empirin / Nu-seals / Rhodine / Rhonal / Solprin / Solprin acid / St. Joseph Aspirin for Adults / Tasprin
Categories
UNII
R16CO5Y76E
CAS number
50-78-2
Weight
Average: 180.1574
Monoisotopic: 180.042258744
Chemical Formula
C9H8O4
InChI Key
BSYNRYMUTXBXSQ-UHFFFAOYSA-N
InChI
InChI=1S/C9H8O4/c1-6(10)13-8-5-3-2-4-7(8)9(11)12/h2-5H,1H3,(H,11,12)
IUPAC Name
2-(acetyloxy)benzoic acid
SMILES
CC(=O)OC1=CC=CC=C1C(O)=O

Pharmacology

Indication

For use in the temporary relief of various forms of pain, inflammation associated with various conditions (including rheumatoid arthritis, juvenile rheumatoid arthritis, systemic lupus erythematosus, osteoarthritis, and ankylosing spondylitis), and is also used to reduce the risk of death and/or nonfatal myocardial infarction in patients with a previous infarction or unstable angina pectoris.

Associated Conditions
Associated Therapies
Pharmacodynamics

Acetylsalicylic acid is an analgesic, antipyretic, antirheumatic, and anti-inflammatory agent. Acetylsalicylic acid's mode of action as an antiinflammatory and antirheumatic agent may be due to inhibition of synthesis and release of prostaglandins. Acetylsalicylic acid appears to produce analgesia by virtue of both a peripheral and CNS effect. Peripherally, acetylsalicylic acid acts by inhibiting the synthesis and release of prostaglandins. Acting centrally, it would appear to produce analgesia at a hypothalamic site in the brain, although the mode of action is not known. Acetylsalicylic acid also acts on the hypothalamus to produce antipyresis; heat dissipation is increased as a result of vasodilation and increased peripheral blood flow. Acetylsalicylic acid's antipyretic activity may also be related to inhibition of synthesis and release of prostaglandins.

Mechanism of action

The analgesic, antipyretic, and anti-inflammatory effects of acetylsalicylic acid are due to actions by both the acetyl and the salicylate portions of the intact molecule as well as by the active salicylate metabolite. Acetylsalicylic acid directly and irreversibly inhibits the activity of both types of cyclooxygenase (COX-1 and COX-2) to decrease the formation of precursors of prostaglandins and thromboxanes from arachidonic acid. This makes acetylsalicylic acid different from other NSAIDS (such as diclofenac and ibuprofen) which are reversible inhibitors. Salicylate may competitively inhibit prostaglandin formation. Acetylsalicylic acid's antirheumatic (nonsteroidal anti-inflammatory) actions are a result of its analgesic and anti-inflammatory mechanisms; the therapeutic effects are not due to pituitary-adrenal stimulation. The platelet aggregation-inhibiting effect of acetylsalicylic acid specifically involves the compound's ability to act as an acetyl donor to cyclooxygenase; the nonacetylated salicylates have no clinically significant effect on platelet aggregation. Irreversible acetylation renders cyclooxygenase inactive, thereby preventing the formation of the aggregating agent thromboxane A2 in platelets. Since platelets lack the ability to synthesize new proteins, the effects persist for the life of the exposed platelets (7-10 days). Acetylsalicylic acid may also inhibit production of the platelet aggregation inhibitor, prostacyclin (prostaglandin I2), by blood vessel endothelial cells; however, inhibition prostacyclin production is not permanent as endothelial cells can produce more cyclooxygenase to replace the non-functional enzyme.

TargetActionsOrganism
AProstaglandin G/H synthase 1
inhibitor
Human
AProstaglandin G/H synthase 2
inhibitor
Human
UAldo-keto reductase family 1 member C1
inhibitor
Human
U5'-AMP-activated protein kinase
activator
Human
UEndothelin-1 receptor
inhibitor
Human
UInhibitor of nuclear factor kappa-B kinase subunit beta
inhibitor
Human
UCellular tumor antigen p53
acetylation
Human
U78 kDa glucose-regulated protein
binding
Human
URibosomal protein S6 kinase alpha-3
inhibitor
Human
UNF-kappa-B inhibitor alpha
inhibitor
Human
UNuclear factor NF-kappa-B
antagonist
Human
Absorption

Absorption is generally rapid and complete following oral administration but may vary according to specific salicylate used, dosage form, and other factors such as tablet dissolution rate and gastric or intraluminal pH.

Volume of distribution
Not Available
Protein binding

High (99.5%) to albumin. Decreases as plasma salicylate concentration increases, with reduced plasma albumin concentration or renal dysfunction, and during pregnancy.

Metabolism

Acetylsalicylic acid is rapidly hydrolyzed primarily in the liver to salicylic acid, which is conjugated with glycine (forming salicyluric acid) and glucuronic acid and excreted largely in the urine.

Route of elimination
Not Available
Half life

The plasma half-life is approximately 15 minutes; that for salicylate lengthens as the dose increases: doses of 300 to 650 mg have a half-life of 3.1 to 3.2 hours; with doses of 1 gram, the half-life is increased to 5 hours and with 2 grams it is increased to about 9 hours.

Clearance
Not Available
Toxicity

Oral, mouse: LD50 = 250 mg/kg; Oral, rabbit: LD50 = 1010 mg/kg; Oral, rat: LD50 = 200 mg/kg. Effects of overdose include: tinnitus, abdominal pain, hypokalemia, hypoglycemia, pyrexia, hyperventilation, dysrhythmia, hypotension, hallucination, renal failure, confusion, seizure, coma, and death.

Affected organisms
  • Humans and other mammals
Pathways
PathwayCategory
Acetylsalicylic Acid Action PathwayDrug action
Pharmacogenomic Effects/ADRs
Interacting Gene/EnzymeAllele nameGenotype(s)Defining Change(s)Type(s)DescriptionDetails
Cytochrome P450 2C9CYP2C9*3(C;C) / (A;C)C AlleleEffect Directly StudiedPatients with this genotype have reduced metabolism of acetylsalicylic acid.Details
Leukotriene C4 synthase---(A;C) / (C;C)C alleleADR Directly StudiedThe presence of this genotype in LTC4S may indicate an increased risk of chronic urticaria when treated with acetylsalicylic acid.Details
Integrin beta-3GPIIIa PlA2(C;C) / (C;T)T > CEffect Directly StudiedPatients with this genotype have increased resistance to the anti-thrombotic effects of aspirin.Details
Cytochrome P450 2C9CYP2C9*6Not Available818delAEffect InferredPoor drug metabolizer, lower dose requirementsDetails
Cytochrome P450 2C9CYP2C9*15Not Available485C>AEffect InferredPoor drug metabolizer, lower dose requirementsDetails
Cytochrome P450 2C9CYP2C9*25Not Available353_362delAGAAATGGAAEffect InferredPoor drug metabolizer, lower dose requirementsDetails
Cytochrome P450 2C9CYP2C9*35Not Available374G>T / 430C>TEffect InferredPoor drug metabolizer, lower dose requirementsDetails
Cytochrome P450 2C9CYP2C9*2Not Available430C>TEffect InferredPoor drug metabolizer, lower dose requirementsDetails
Cytochrome P450 2C9CYP2C9*4Not Available1076T>CEffect InferredPoor drug metabolizer, lower dose requirementsDetails
Cytochrome P450 2C9CYP2C9*5Not Available1080C>GEffect InferredPoor drug metabolizer, lower dose requirementsDetails
Cytochrome P450 2C9CYP2C9*8Not Available449G>AEffect InferredPoor drug metabolizer, lower dose requirementsDetails
Cytochrome P450 2C9CYP2C9*11Not Available1003C>TEffect InferredPoor drug metabolizer, lower dose requirementsDetails
Cytochrome P450 2C9CYP2C9*12Not Available1465C>TEffect InferredPoor drug metabolizer, lower dose requirementsDetails
Cytochrome P450 2C9CYP2C9*13Not Available269T>CEffect InferredPoor drug metabolizer, lower dose requirementsDetails
Cytochrome P450 2C9CYP2C9*14Not Available374G>AEffect InferredPoor drug metabolizer, lower dose requirementsDetails
Cytochrome P450 2C9CYP2C9*16Not Available895A>GEffect InferredPoor drug metabolizer, lower dose requirementsDetails
Cytochrome P450 2C9CYP2C9*18Not Available1075A>C / 1190A>C  … show all Effect InferredPoor drug metabolizer, lower dose requirementsDetails
Cytochrome P450 2C9CYP2C9*26Not Available389C>GEffect InferredPoor drug metabolizer, lower dose requirementsDetails
Cytochrome P450 2C9CYP2C9*28Not Available641A>TEffect InferredPoor drug metabolizer, lower dose requirementsDetails
Cytochrome P450 2C9CYP2C9*30Not Available1429G>AEffect InferredPoor drug metabolizer, lower dose requirementsDetails
Cytochrome P450 2C9CYP2C9*33Not Available395G>AEffect InferredPoor drug metabolizer, lower dose requirementsDetails

Interactions

Drug Interactions
DrugInteractionDrug group
(4R)-limoneneThe risk or severity of adverse effects can be increased when (4R)-limonene is combined with Acetylsalicylic acid.Investigational
16-BromoepiandrosteroneThe risk or severity of adverse effects can be increased when Acetylsalicylic acid is combined with 16-Bromoepiandrosterone.Investigational
19-norandrostenedioneThe risk or severity of adverse effects can be increased when Acetylsalicylic acid is combined with 19-norandrostenedione.Experimental, Illicit
5-androstenedioneThe risk or severity of adverse effects can be increased when Acetylsalicylic acid is combined with 5-androstenedione.Experimental, Illicit
AbciximabThe risk or severity of adverse effects can be increased when Abciximab is combined with Acetylsalicylic acid.Approved
AbirateroneThe serum concentration of Acetylsalicylic acid can be increased when it is combined with Abiraterone.Approved
AcarboseAcetylsalicylic acid may increase the hypoglycemic activities of Acarbose.Approved, Investigational
AcebutololAcetylsalicylic acid may decrease the antihypertensive activities of Acebutolol.Approved, Investigational
AcemetacinThe risk or severity of adverse effects can be increased when Acetylsalicylic acid is combined with Acemetacin.Approved, Experimental, Investigational
AcenocoumarolAcetylsalicylic acid may increase the anticoagulant activities of Acenocoumarol.Approved, Investigational
AcetazolamideThe risk or severity of adverse effects can be increased when Acetylsalicylic acid is combined with Acetazolamide.Approved, Vet Approved
Acetyl sulfisoxazoleThe metabolism of Acetylsalicylic acid can be decreased when combined with Acetyl sulfisoxazole.Approved, Vet Approved
AdapaleneThe risk or severity of adverse effects can be increased when Adapalene is combined with Acetylsalicylic acid.Approved
AlaproclateAlaproclate may increase the antiplatelet activities of Acetylsalicylic acid.Experimental
AlbiglutideAcetylsalicylic acid may increase the hypoglycemic activities of Albiglutide.Approved
AlclofenacThe risk or severity of adverse effects can be increased when Alclofenac is combined with Acetylsalicylic acid.Approved, Withdrawn
AlclometasoneThe risk or severity of adverse effects can be increased when Acetylsalicylic acid is combined with Alclometasone.Approved
AldosteroneThe risk or severity of adverse effects can be increased when Acetylsalicylic acid is combined with Aldosterone.Experimental, Investigational
Alendronic acidThe risk or severity of adverse effects can be increased when Acetylsalicylic acid is combined with Alendronic acid.Approved
AliskirenAcetylsalicylic acid may decrease the antihypertensive activities of Aliskiren.Approved, Investigational
AlminoprofenThe risk or severity of adverse effects can be increased when Alminoprofen is combined with Acetylsalicylic acid.Experimental
AlogliptinAcetylsalicylic acid may increase the hypoglycemic activities of Alogliptin.Approved
AloxiprinThe risk or severity of adverse effects can be increased when Acetylsalicylic acid is combined with Aloxiprin.Experimental
AlprenololAcetylsalicylic acid may decrease the antihypertensive activities of Alprenolol.Approved, Withdrawn
AlprostadilThe risk or severity of adverse effects can be increased when Alprostadil is combined with Acetylsalicylic acid.Approved, Investigational
AlteplaseThe risk or severity of adverse effects can be increased when Acetylsalicylic acid is combined with Alteplase.Approved
AmcinonideThe risk or severity of adverse effects can be increased when Acetylsalicylic acid is combined with Amcinonide.Approved
AmikacinAcetylsalicylic acid may decrease the excretion rate of Amikacin which could result in a higher serum level.Approved, Investigational, Vet Approved
AmilorideAcetylsalicylic acid may decrease the antihypertensive activities of Amiloride.Approved
AmiodaroneThe metabolism of Acetylsalicylic acid can be decreased when combined with Amiodarone.Approved, Investigational
Ammonium chlorideThe serum concentration of Acetylsalicylic acid can be increased when it is combined with Ammonium chloride.Approved, Investigational, Vet Approved
AnagrelideThe risk or severity of adverse effects can be increased when Anagrelide is combined with Acetylsalicylic acid.Approved
AncrodAcetylsalicylic acid may increase the anticoagulant activities of Ancrod.Approved, Investigational
AndrographolideThe risk or severity of adverse effects can be increased when Andrographolide is combined with Acetylsalicylic acid.Investigational
AndrostenedioneThe risk or severity of adverse effects can be increased when Acetylsalicylic acid is combined with Androstenedione.Experimental, Illicit
AnecortaveThe risk or severity of adverse effects can be increased when Acetylsalicylic acid is combined with Anecortave.Investigational
anecortave acetateThe risk or severity of adverse effects can be increased when Acetylsalicylic acid is combined with anecortave acetate.Investigational
AnisodamineThe risk or severity of adverse effects can be increased when Anisodamine is combined with Acetylsalicylic acid.Investigational
AnistreplaseThe risk or severity of adverse effects can be increased when Acetylsalicylic acid is combined with Anistreplase.Approved
Antithrombin III humanAcetylsalicylic acid may increase the anticoagulant activities of Antithrombin III human.Approved
ApalutamideThe serum concentration of Acetylsalicylic acid can be decreased when it is combined with Apalutamide.Approved, Investigational
ApixabanThe risk or severity of adverse effects can be increased when Acetylsalicylic acid is combined with Apixaban.Approved
ApocyninThe risk or severity of adverse effects can be increased when Apocynin is combined with Acetylsalicylic acid.Investigational
ApramycinAcetylsalicylic acid may decrease the excretion rate of Apramycin which could result in a higher serum level.Experimental, Vet Approved
ApremilastThe risk or severity of adverse effects can be increased when Apremilast is combined with Acetylsalicylic acid.Approved, Investigational
AprepitantThe metabolism of Acetylsalicylic acid can be increased when combined with Aprepitant.Approved, Investigational
AprotininThe therapeutic efficacy of Acetylsalicylic acid can be decreased when used in combination with Aprotinin.Approved, Investigational, Withdrawn
ArbekacinAcetylsalicylic acid may decrease the excretion rate of Arbekacin which could result in a higher serum level.Approved, Investigational
ArdeparinAcetylsalicylic acid may increase the anticoagulant activities of Ardeparin.Approved, Investigational, Withdrawn
ArgatrobanThe risk or severity of adverse effects can be increased when Argatroban is combined with Acetylsalicylic acid.Approved, Investigational
ArotinololAcetylsalicylic acid may decrease the antihypertensive activities of Arotinolol.Investigational
AsenapineAcetylsalicylic acid may decrease the antihypertensive activities of Asenapine.Approved
AstaxanthinThe risk or severity of adverse effects can be increased when Acetylsalicylic acid is combined with Astaxanthin.Investigational
AtamestaneThe risk or severity of adverse effects can be increased when Acetylsalicylic acid is combined with Atamestane.Investigational
AtenololAcetylsalicylic acid may decrease the antihypertensive activities of Atenolol.Approved
AzapropazoneThe risk or severity of adverse effects can be increased when Azapropazone is combined with Acetylsalicylic acid.Withdrawn
AzelastineThe risk or severity of adverse effects can be increased when Azelastine is combined with Acetylsalicylic acid.Approved
Azficel-TThe risk or severity of adverse effects can be increased when Acetylsalicylic acid is combined with Azficel-T.Approved, Investigational
Azilsartan medoxomilThe risk or severity of adverse effects can be increased when Azilsartan medoxomil is combined with Acetylsalicylic acid.Approved, Investigational
AzosemideThe therapeutic efficacy of Azosemide can be decreased when used in combination with Acetylsalicylic acid.Investigational
BatroxobinThe risk or severity of adverse effects can be increased when Acetylsalicylic acid is combined with Batroxobin.Experimental
BazedoxifeneAcetylsalicylic acid may increase the thrombogenic activities of Bazedoxifene.Approved, Investigational
BecaplerminAcetylsalicylic acid may increase the anticoagulant activities of Becaplermin.Approved, Investigational
Beclomethasone dipropionateThe risk or severity of adverse effects can be increased when Acetylsalicylic acid is combined with Beclomethasone dipropionate.Approved, Investigational
BefunololAcetylsalicylic acid may decrease the antihypertensive activities of Befunolol.Experimental
BekanamycinAcetylsalicylic acid may decrease the excretion rate of Bekanamycin which could result in a higher serum level.Experimental
BemiparinThe risk or severity of adverse effects can be increased when Acetylsalicylic acid is combined with Bemiparin.Approved, Investigational
BenazeprilThe therapeutic efficacy of Benazepril can be decreased when used in combination with Acetylsalicylic acid.Approved, Investigational
BendazacThe risk or severity of adverse effects can be increased when Bendazac is combined with Acetylsalicylic acid.Experimental
BendroflumethiazideThe therapeutic efficacy of Bendroflumethiazide can be decreased when used in combination with Acetylsalicylic acid.Approved
BenorilateThe risk or severity of adverse effects can be increased when Benorilate is combined with Acetylsalicylic acid.Experimental
BenoxaprofenThe risk or severity of adverse effects can be increased when Benoxaprofen is combined with Acetylsalicylic acid.Withdrawn
BenzthiazideThe therapeutic efficacy of Benzthiazide can be decreased when used in combination with Acetylsalicylic acid.Approved
BenzydamineThe risk or severity of adverse effects can be increased when Benzydamine is combined with Acetylsalicylic acid.Approved
BeraprostThe risk or severity of adverse effects can be increased when Beraprost is combined with Acetylsalicylic acid.Investigational
BetamethasoneThe risk or severity of adverse effects can be increased when Acetylsalicylic acid is combined with Betamethasone.Approved, Vet Approved
BetaxololAcetylsalicylic acid may decrease the antihypertensive activities of Betaxolol.Approved, Investigational
BetrixabanThe risk or severity of bleeding can be increased when Betrixaban is combined with Acetylsalicylic acid.Approved, Investigational
BevantololAcetylsalicylic acid may decrease the antihypertensive activities of Bevantolol.Approved
BevoniumThe risk or severity of adverse effects can be increased when Bevonium is combined with Acetylsalicylic acid.Experimental
BimatoprostThe therapeutic efficacy of Bimatoprost can be decreased when used in combination with Acetylsalicylic acid.Approved, Investigational
BisoprololAcetylsalicylic acid may decrease the antihypertensive activities of Bisoprolol.Approved
BivalirudinAcetylsalicylic acid may increase the anticoagulant activities of Bivalirudin.Approved, Investigational
BopindololAcetylsalicylic acid may decrease the antihypertensive activities of Bopindolol.Approved
BrinaseThe risk or severity of adverse effects can be increased when Acetylsalicylic acid is combined with Brinase.Experimental
BrinzolamideThe risk or severity of adverse effects can be increased when Acetylsalicylic acid is combined with Brinzolamide.Approved
BromocriptineAcetylsalicylic acid may increase the hypoglycemic activities of Bromocriptine.Approved, Investigational
BucillamineThe risk or severity of adverse effects can be increased when Bucillamine is combined with Acetylsalicylic acid.Investigational
BucindololAcetylsalicylic acid may decrease the antihypertensive activities of Bucindolol.Investigational
BudesonideThe risk or severity of adverse effects can be increased when Acetylsalicylic acid is combined with Budesonide.Approved
BuflomedilThe risk or severity of adverse effects can be increased when Buflomedil is combined with Acetylsalicylic acid.Experimental
BufuralolAcetylsalicylic acid may decrease the antihypertensive activities of Bufuralol.Experimental, Investigational
BumadizoneThe risk or severity of adverse effects can be increased when Bumadizone is combined with Acetylsalicylic acid.Experimental
BumetanideThe therapeutic efficacy of Bumetanide can be decreased when used in combination with Acetylsalicylic acid.Approved
BupranololAcetylsalicylic acid may decrease the antihypertensive activities of Bupranolol.Approved
ButylphthalideThe risk or severity of adverse effects can be increased when Butylphthalide is combined with Acetylsalicylic acid.Investigational
CanagliflozinAcetylsalicylic acid may increase the hypoglycemic activities of Canagliflozin.Approved
CandesartanThe risk or severity of adverse effects can be increased when Candesartan is combined with Acetylsalicylic acid.Experimental
Candesartan cilexetilThe risk or severity of adverse effects can be increased when Candesartan cilexetil is combined with Acetylsalicylic acid.Approved
CandoxatrilThe therapeutic efficacy of Candoxatril can be decreased when used in combination with Acetylsalicylic acid.Experimental
CangrelorThe risk or severity of adverse effects can be increased when Cangrelor is combined with Acetylsalicylic acid.Approved
CapecitabineThe metabolism of Acetylsalicylic acid can be decreased when combined with Capecitabine.Approved, Investigational
CaplacizumabThe risk or severity of adverse effects can be increased when Acetylsalicylic acid is combined with Caplacizumab.Investigational
CaptoprilThe therapeutic efficacy of Captopril can be decreased when used in combination with Acetylsalicylic acid.Approved
CarbamazepineThe metabolism of Acetylsalicylic acid can be increased when combined with Carbamazepine.Approved, Investigational
Carbaspirin calciumThe risk or severity of adverse effects can be increased when Carbaspirin calcium is combined with Acetylsalicylic acid.Experimental, Investigational
Carboprost TromethamineThe therapeutic efficacy of Carboprost Tromethamine can be decreased when used in combination with Acetylsalicylic acid.Approved
CarisoprodolThe serum concentration of the active metabolites of Carisoprodol can be increased when Carisoprodol is used in combination with Acetylsalicylic acid.Approved
CarteololAcetylsalicylic acid may decrease the antihypertensive activities of Carteolol.Approved
CarvedilolAcetylsalicylic acid may decrease the antihypertensive activities of Carvedilol.Approved, Investigational
CastanospermineThe risk or severity of adverse effects can be increased when Castanospermine is combined with Acetylsalicylic acid.Experimental
CelecoxibThe risk or severity of adverse effects can be increased when Acetylsalicylic acid is combined with Celecoxib.Approved, Investigational
CeliprololAcetylsalicylic acid may decrease the antihypertensive activities of Celiprolol.Approved, Investigational
CeritinibThe serum concentration of Acetylsalicylic acid can be increased when it is combined with Ceritinib.Approved
CertoparinAcetylsalicylic acid may increase the anticoagulant activities of Certoparin.Approved, Investigational
ChloroquineThe risk or severity of adverse effects can be increased when Chloroquine is combined with Acetylsalicylic acid.Approved, Investigational, Vet Approved
ChlorothiazideThe therapeutic efficacy of Chlorothiazide can be decreased when used in combination with Acetylsalicylic acid.Approved, Vet Approved
ChlorotrianiseneAcetylsalicylic acid may increase the thrombogenic activities of Chlorotrianisene.Investigational, Withdrawn
ChlorpropamideAcetylsalicylic acid may increase the hypoglycemic activities of Chlorpropamide.Approved, Investigational
ChlorthalidoneThe therapeutic efficacy of Chlorthalidone can be decreased when used in combination with Acetylsalicylic acid.Approved
CholecalciferolThe metabolism of Acetylsalicylic acid can be decreased when combined with Cholecalciferol.Approved, Nutraceutical
CholestyramineCholestyramine can cause a decrease in the absorption of Acetylsalicylic acid resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved, Investigational
CiclesonideThe risk or severity of adverse effects can be increased when Acetylsalicylic acid is combined with Ciclesonide.Approved, Investigational
CilazaprilThe therapeutic efficacy of Cilazapril can be decreased when used in combination with Acetylsalicylic acid.Approved
CilostazolThe risk or severity of adverse effects can be increased when Cilostazol is combined with Acetylsalicylic acid.Approved, Investigational
CinoxacinAcetylsalicylic acid may increase the neuroexcitatory activities of Cinoxacin.Approved, Investigational, Withdrawn
CiprofloxacinAcetylsalicylic acid may increase the neuroexcitatory activities of Ciprofloxacin.Approved, Investigational
CitalopramCitalopram may increase the antiplatelet activities of Acetylsalicylic acid.Approved
Citric AcidAcetylsalicylic acid may increase the anticoagulant activities of Citric Acid.Approved, Nutraceutical, Vet Approved
ClobetasolThe risk or severity of adverse effects can be increased when Acetylsalicylic acid is combined with Clobetasol.Approved, Investigational
Clobetasol propionateThe risk or severity of adverse effects can be increased when Acetylsalicylic acid is combined with Clobetasol propionate.Approved
ClobetasoneThe risk or severity of adverse effects can be increased when Acetylsalicylic acid is combined with Clobetasone.Approved
ClocortoloneThe risk or severity of adverse effects can be increased when Acetylsalicylic acid is combined with Clocortolone.Approved
ClonixinThe risk or severity of adverse effects can be increased when Clonixin is combined with Acetylsalicylic acid.Approved
ClopidogrelThe risk or severity of adverse effects can be increased when Clopidogrel is combined with Acetylsalicylic acid.Approved
CloprostenolThe therapeutic efficacy of Cloprostenol can be decreased when used in combination with Acetylsalicylic acid.Vet Approved
CloranololAcetylsalicylic acid may decrease the antihypertensive activities of Cloranolol.Experimental
CloricromenThe risk or severity of adverse effects can be increased when Cloricromen is combined with Acetylsalicylic acid.Experimental
ClorindioneAcetylsalicylic acid may increase the anticoagulant activities of Clorindione.Experimental
ClotrimazoleThe metabolism of Acetylsalicylic acid can be decreased when combined with Clotrimazole.Approved, Vet Approved
ColesevelamColesevelam can cause a decrease in the absorption of Acetylsalicylic acid resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved
ColestipolColestipol can cause a decrease in the absorption of Acetylsalicylic acid resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved
Collagenase clostridium histolyticumThe risk or severity of adverse effects can be increased when Acetylsalicylic acid is combined with Collagenase clostridium histolyticum.Approved, Investigational
Conjugated estrogensAcetylsalicylic acid may increase the thrombogenic activities of Conjugated estrogens.Approved
Cortexolone 17α-propionateThe risk or severity of adverse effects can be increased when Acetylsalicylic acid is combined with Cortexolone 17α-propionate.Investigational
CorticosteroneThe risk or severity of adverse effects can be increased when Acetylsalicylic acid is combined with Corticosterone.Experimental
Cortisone acetateThe risk or severity of adverse effects can be increased when Acetylsalicylic acid is combined with Cortisone acetate.Approved, Investigational
CrisaboroleThe metabolism of Acetylsalicylic acid can be decreased when combined with Crisaborole.Approved, Investigational
CurcuminThe risk or severity of adverse effects can be increased when Curcumin is combined with Acetylsalicylic acid.Approved, Investigational
CyclopenthiazideThe therapeutic efficacy of Cyclopenthiazide can be decreased when used in combination with Acetylsalicylic acid.Experimental
CyclosporineAcetylsalicylic acid may increase the nephrotoxic activities of Cyclosporine.Approved, Investigational, Vet Approved
Dabigatran etexilateAcetylsalicylic acid may increase the anticoagulant activities of Dabigatran etexilate.Approved
DabrafenibThe serum concentration of Acetylsalicylic acid can be decreased when it is combined with Dabrafenib.Approved, Investigational
DaidzeinAcetylsalicylic acid may increase the thrombogenic activities of Daidzein.Experimental
DalteparinAcetylsalicylic acid may increase the anticoagulant activities of Dalteparin.Approved
DanaparoidAcetylsalicylic acid may increase the anticoagulant activities of Danaparoid.Approved, Withdrawn
DapagliflozinAcetylsalicylic acid may increase the hypoglycemic activities of Dapagliflozin.Approved
DapoxetineDapoxetine may increase the antiplatelet activities of Acetylsalicylic acid.Investigational
DarexabanAcetylsalicylic acid may increase the anticoagulant activities of Darexaban.Investigational
DasatinibDasatinib may increase the anticoagulant activities of Acetylsalicylic acid.Approved, Investigational
DeferasiroxThe serum concentration of Acetylsalicylic acid can be increased when it is combined with Deferasirox.Approved, Investigational
DefibrotideThe risk or severity of adverse effects can be increased when Defibrotide is combined with Acetylsalicylic acid.Approved, Investigational
DeflazacortThe risk or severity of adverse effects can be increased when Acetylsalicylic acid is combined with Deflazacort.Approved, Investigational
DelaprilThe therapeutic efficacy of Delapril can be decreased when used in combination with Acetylsalicylic acid.Experimental
DelavirdineThe metabolism of Acetylsalicylic acid can be decreased when combined with Delavirdine.Approved
Deoxycholic AcidThe risk or severity of adverse effects can be increased when Acetylsalicylic acid is combined with Deoxycholic Acid.Approved
DersalazineThe risk or severity of adverse effects can be increased when Acetylsalicylic acid is combined with Dersalazine.Investigational
DesipramineAcetylsalicylic acid may decrease the antihypertensive activities of Desipramine.Approved, Investigational
DesirudinAcetylsalicylic acid may increase the anticoagulant activities of Desirudin.Approved
DesmopressinThe risk or severity of adverse effects can be increased when Acetylsalicylic acid is combined with Desmopressin.Approved
DesmoteplaseThe risk or severity of adverse effects can be increased when Acetylsalicylic acid is combined with Desmoteplase.Investigational
DesonideThe risk or severity of adverse effects can be increased when Acetylsalicylic acid is combined with Desonide.Approved, Investigational
DesoximetasoneThe risk or severity of adverse effects can be increased when Acetylsalicylic acid is combined with Desoximetasone.Approved
Desoxycorticosterone acetateThe risk or severity of adverse effects can be increased when Acetylsalicylic acid is combined with Desoxycorticosterone acetate.Approved
Desoxycorticosterone PivalateThe risk or severity of adverse effects can be increased when Acetylsalicylic acid is combined with Desoxycorticosterone Pivalate.Experimental, Vet Approved
DesvenlafaxineDesvenlafaxine may increase the antiplatelet activities of Acetylsalicylic acid.Approved, Investigational
DexamethasoneThe risk or severity of adverse effects can be increased when Acetylsalicylic acid is combined with Dexamethasone.Approved, Investigational, Vet Approved
Dexamethasone isonicotinateThe risk or severity of adverse effects can be increased when Acetylsalicylic acid is combined with Dexamethasone isonicotinate.Vet Approved
DexketoprofenThe risk or severity of adverse effects can be increased when Acetylsalicylic acid is combined with Dexketoprofen.Approved, Investigational
DextranAcetylsalicylic acid may increase the anticoagulant activities of Dextran.Approved, Investigational, Vet Approved
DibekacinAcetylsalicylic acid may decrease the excretion rate of Dibekacin which could result in a higher serum level.Experimental
Dibotermin alfaThe risk or severity of adverse effects can be increased when Acetylsalicylic acid is combined with Dibotermin alfa.Approved, Investigational
DiclofenacThe risk or severity of adverse effects can be increased when Diclofenac is combined with Acetylsalicylic acid.Approved, Vet Approved
DiclofenamideThe risk or severity of adverse effects can be increased when Acetylsalicylic acid is combined with Diclofenamide.Approved, Investigational
DicoumarolAcetylsalicylic acid may increase the anticoagulant activities of Dicoumarol.Approved
DienestrolAcetylsalicylic acid may increase the thrombogenic activities of Dienestrol.Approved, Investigational
DiethylstilbestrolAcetylsalicylic acid may increase the thrombogenic activities of Diethylstilbestrol.Approved, Investigational
DifenpiramideThe risk or severity of adverse effects can be increased when Difenpiramide is combined with Acetylsalicylic acid.Experimental
DiflorasoneThe risk or severity of adverse effects can be increased when Acetylsalicylic acid is combined with Diflorasone.Approved
DifluocortoloneThe risk or severity of adverse effects can be increased when Acetylsalicylic acid is combined with Difluocortolone.Approved, Investigational, Withdrawn
DifluprednateThe risk or severity of adverse effects can be increased when Acetylsalicylic acid is combined with Difluprednate.Approved
DigoxinThe serum concentration of Digoxin can be increased when it is combined with Acetylsalicylic acid.Approved
DihydrostreptomycinAcetylsalicylic acid may decrease the excretion rate of Dihydrostreptomycin which could result in a higher serum level.Investigational, Vet Approved
DiltiazemDiltiazem may increase the anticoagulant activities of Acetylsalicylic acid.Approved, Investigational
DinoprostThe therapeutic efficacy of Dinoprost can be decreased when used in combination with Acetylsalicylic acid.Investigational
Dinoprost TromethamineThe therapeutic efficacy of Dinoprost Tromethamine can be decreased when used in combination with Acetylsalicylic acid.Approved, Vet Approved
DinoprostoneThe therapeutic efficacy of Dinoprostone can be decreased when used in combination with Acetylsalicylic acid.Approved
DiphenadioneAcetylsalicylic acid may increase the anticoagulant activities of Diphenadione.Experimental
DipyridamoleThe risk or severity of adverse effects can be increased when Dipyridamole is combined with Acetylsalicylic acid.Approved
DisopyramideAcetylsalicylic acid may increase the hypoglycemic activities of Disopyramide.Approved
DitazoleThe risk or severity of adverse effects can be increased when Acetylsalicylic acid is combined with Ditazole.Approved, Withdrawn
DorzolamideThe risk or severity of adverse effects can be increased when Acetylsalicylic acid is combined with Dorzolamide.Approved
DosulepinThe metabolism of Acetylsalicylic acid can be decreased when combined with Dosulepin.Approved
DrospirenoneThe risk or severity of adverse effects can be increased when Acetylsalicylic acid is combined with Drospirenone.Approved
Drotrecogin alfaThe risk or severity of adverse effects can be increased when Acetylsalicylic acid is combined with Drotrecogin alfa.Approved, Investigational, Withdrawn
DulaglutideAcetylsalicylic acid may increase the hypoglycemic activities of Dulaglutide.Approved, Investigational
DuloxetineDuloxetine may increase the antiplatelet activities of Acetylsalicylic acid.Approved
DuvelisibThe risk or severity of adverse effects can be increased when Duvelisib is combined with Acetylsalicylic acid.Investigational
E-6201The risk or severity of adverse effects can be increased when E-6201 is combined with Acetylsalicylic acid.Investigational
Edetic AcidAcetylsalicylic acid may increase the anticoagulant activities of Edetic Acid.Approved, Vet Approved
EdoxabanAcetylsalicylic acid may increase the anticoagulant activities of Edoxaban.Approved
EfavirenzThe metabolism of Acetylsalicylic acid can be decreased when combined with Efavirenz.Approved, Investigational
EmpagliflozinAcetylsalicylic acid may increase the hypoglycemic activities of Empagliflozin.Approved
EnalaprilThe therapeutic efficacy of Enalapril can be decreased when used in combination with Acetylsalicylic acid.Approved, Vet Approved
EnalaprilatThe therapeutic efficacy of Enalaprilat can be decreased when used in combination with Acetylsalicylic acid.Approved
EnoxacinAcetylsalicylic acid may increase the neuroexcitatory activities of Enoxacin.Approved, Investigational
EnoxaparinAcetylsalicylic acid may increase the anticoagulant activities of Enoxaparin.Approved
EnprostilThe therapeutic efficacy of Enprostil can be decreased when used in combination with Acetylsalicylic acid.Experimental
EpanololAcetylsalicylic acid may decrease the antihypertensive activities of Epanolol.Experimental
EpimestrolAcetylsalicylic acid may increase the thrombogenic activities of Epimestrol.Experimental
EpinastineThe risk or severity of adverse effects can be increased when Epinastine is combined with Acetylsalicylic acid.Approved, Investigational
EpirizoleThe risk or severity of adverse effects can be increased when Epirizole is combined with Acetylsalicylic acid.Approved
EpitizideThe therapeutic efficacy of Epitizide can be decreased when used in combination with Acetylsalicylic acid.Experimental
EplerenoneAcetylsalicylic acid may decrease the antihypertensive activities of Eplerenone.Approved
EplivanserinThe risk or severity of adverse effects can be increased when Eplivanserin is combined with Acetylsalicylic acid.Investigational
eplivanserineThe risk or severity of adverse effects can be increased when eplivanserine is combined with Acetylsalicylic acid.Investigational
EpoprostenolThe risk or severity of adverse effects can be increased when Epoprostenol is combined with Acetylsalicylic acid.Approved
EprosartanThe risk or severity of adverse effects can be increased when Eprosartan is combined with Acetylsalicylic acid.Approved
EptifibatideThe risk or severity of adverse effects can be increased when Eptifibatide is combined with Acetylsalicylic acid.Approved, Investigational
EquileninThe risk or severity of adverse effects can be increased when Acetylsalicylic acid is combined with Equilenin.Experimental
EquilinThe risk or severity of adverse effects can be increased when Acetylsalicylic acid is combined with Equilin.Approved
EquolAcetylsalicylic acid may increase the thrombogenic activities of Equol.Investigational
EsatenololAcetylsalicylic acid may decrease the antihypertensive activities of Esatenolol.Experimental
EscitalopramEscitalopram may increase the antiplatelet activities of Acetylsalicylic acid.Approved, Investigational
EsmololAcetylsalicylic acid may decrease the antihypertensive activities of Esmolol.Approved
EstradiolAcetylsalicylic acid may increase the thrombogenic activities of Estradiol.Approved, Investigational, Vet Approved
Estradiol acetateAcetylsalicylic acid may increase the thrombogenic activities of Estradiol acetate.Approved, Investigational, Vet Approved
Estradiol cypionateAcetylsalicylic acid may increase the thrombogenic activities of Estradiol cypionate.Approved, Investigational, Vet Approved
Estradiol valerateAcetylsalicylic acid may increase the thrombogenic activities of Estradiol valerate.Approved, Investigational, Vet Approved
EstriolAcetylsalicylic acid may increase the thrombogenic activities of Estriol.Approved, Investigational, Vet Approved
Estrogens, esterifiedAcetylsalicylic acid may increase the thrombogenic activities of Estrogens, esterified.Approved
EstroneThe risk or severity of adverse effects can be increased when Acetylsalicylic acid is combined with Estrone.Approved
Estrone sulfateThe risk or severity of adverse effects can be increased when Acetylsalicylic acid is combined with Estrone sulfate.Approved
Etacrynic acidThe therapeutic efficacy of Etacrynic acid can be decreased when used in combination with Acetylsalicylic acid.Approved, Investigational
EthanolThe risk or severity of adverse effects can be increased when Ethanol is combined with Acetylsalicylic acid.Approved
EthenzamideThe risk or severity of adverse effects can be increased when Ethenzamide is combined with Acetylsalicylic acid.Experimental
Ethinyl EstradiolAcetylsalicylic acid may increase the thrombogenic activities of Ethinyl Estradiol.Approved
EthoxzolamideThe risk or severity of adverse effects can be increased when Acetylsalicylic acid is combined with Ethoxzolamide.Withdrawn
Ethyl biscoumacetateAcetylsalicylic acid may increase the anticoagulant activities of Ethyl biscoumacetate.Withdrawn
Etidronic acidThe risk or severity of adverse effects can be increased when Acetylsalicylic acid is combined with Etidronic acid.Approved
EtodolacThe risk or severity of adverse effects can be increased when Acetylsalicylic acid is combined with Etodolac.Approved, Investigational, Vet Approved
EtofenamateThe risk or severity of adverse effects can be increased when Etofenamate is combined with Acetylsalicylic acid.Approved, Investigational
EtoperidoneEtoperidone may increase the antiplatelet activities of Acetylsalicylic acid.Withdrawn
EtoricoxibThe risk or severity of adverse effects can be increased when Acetylsalicylic acid is combined with Etoricoxib.Approved, Investigational
EtravirineThe metabolism of Acetylsalicylic acid can be decreased when combined with Etravirine.Approved
Evening primrose oilThe risk or severity of adverse effects can be increased when Evening primrose oil is combined with Acetylsalicylic acid.Investigational, Nutraceutical
ExenatideAcetylsalicylic acid may increase the hypoglycemic activities of Exenatide.Approved, Investigational
ExisulindThe risk or severity of adverse effects can be increased when Exisulind is combined with Acetylsalicylic acid.Investigational
FelbinacThe risk or severity of adverse effects can be increased when Felbinac is combined with Acetylsalicylic acid.Experimental
FelodipineThe metabolism of Acetylsalicylic acid can be decreased when combined with Felodipine.Approved, Investigational
FenbufenThe risk or severity of adverse effects can be increased when Fenbufen is combined with Acetylsalicylic acid.Approved
FenprostaleneThe therapeutic efficacy of Fenprostalene can be decreased when used in combination with Acetylsalicylic acid.Vet Approved
FentiazacThe risk or severity of adverse effects can be increased when Fentiazac is combined with Acetylsalicylic acid.Experimental
FeprazoneThe risk or severity of adverse effects can be increased when Feprazone is combined with Acetylsalicylic acid.Experimental
Ferulic acidThe risk or severity of adverse effects can be increased when Ferulic acid is combined with Acetylsalicylic acid.Experimental
FibrinolysinThe risk or severity of adverse effects can be increased when Acetylsalicylic acid is combined with Fibrinolysin.Investigational
FimasartanThe risk or severity of adverse effects can be increased when Fimasartan is combined with Acetylsalicylic acid.Approved, Investigational
FleroxacinAcetylsalicylic acid may increase the neuroexcitatory activities of Fleroxacin.Approved
FloctafenineThe risk or severity of adverse effects can be increased when Floctafenine is combined with Acetylsalicylic acid.Approved, Withdrawn
FloxuridineThe metabolism of Acetylsalicylic acid can be decreased when combined with Floxuridine.Approved
FluasteroneThe risk or severity of adverse effects can be increased when Acetylsalicylic acid is combined with Fluasterone.Investigational
FluconazoleThe metabolism of Acetylsalicylic acid can be decreased when combined with Fluconazole.Approved, Investigational
FludrocortisoneThe risk or severity of adverse effects can be increased when Acetylsalicylic acid is combined with Fludrocortisone.Approved, Investigational
FluindioneAcetylsalicylic acid may increase the anticoagulant activities of Fluindione.Approved, Investigational
FlumequineAcetylsalicylic acid may increase the neuroexcitatory activities of Flumequine.Withdrawn
FlumethasoneThe risk or severity of adverse effects can be increased when Acetylsalicylic acid is combined with Flumethasone.Approved, Vet Approved
FlunisolideThe risk or severity of adverse effects can be increased when Acetylsalicylic acid is combined with Flunisolide.Approved, Investigational
FlunixinThe risk or severity of adverse effects can be increased when Flunixin is combined with Acetylsalicylic acid.Vet Approved
FlunoxaprofenThe risk or severity of adverse effects can be increased when Flunoxaprofen is combined with Acetylsalicylic acid.Experimental
Fluocinolone AcetonideThe risk or severity of adverse effects can be increased when Acetylsalicylic acid is combined with Fluocinolone Acetonide.Approved, Investigational, Vet Approved
FluocinonideThe risk or severity of adverse effects can be increased when Acetylsalicylic acid is combined with Fluocinonide.Approved, Investigational
FluocortoloneThe risk or severity of adverse effects can be increased when Acetylsalicylic acid is combined with Fluocortolone.Approved, Withdrawn
FluorometholoneThe risk or severity of adverse effects can be increased when Acetylsalicylic acid is combined with Fluorometholone.Approved, Investigational
FluorouracilThe metabolism of Acetylsalicylic acid can be decreased when combined with Fluorouracil.Approved
FluoxetineFluoxetine may increase the antiplatelet activities of Acetylsalicylic acid.Approved, Vet Approved
FluprednideneThe risk or severity of adverse effects can be increased when Acetylsalicylic acid is combined with Fluprednidene.Approved, Withdrawn
FluprednisoloneThe risk or severity of adverse effects can be increased when Acetylsalicylic acid is combined with Fluprednisolone.Approved
FluprostenolThe therapeutic efficacy of Fluprostenol can be decreased when used in combination with Acetylsalicylic acid.Vet Approved
FlurandrenolideThe risk or severity of adverse effects can be increased when Acetylsalicylic acid is combined with Flurandrenolide.Approved
FluticasoneThe risk or severity of adverse effects can be increased when Acetylsalicylic acid is combined with Fluticasone.Approved, Experimental, Investigational
Fluticasone furoateThe risk or severity of adverse effects can be increased when Acetylsalicylic acid is combined with Fluticasone furoate.Approved
Fluticasone propionateThe risk or severity of adverse effects can be increased when Acetylsalicylic acid is combined with Fluticasone propionate.Approved
FluvastatinThe metabolism of Acetylsalicylic acid can be decreased when combined with Fluvastatin.Approved
FluvoxamineFluvoxamine may increase the antiplatelet activities of Acetylsalicylic acid.Approved, Investigational
Folic AcidThe therapeutic efficacy of Folic Acid can be decreased when used in combination with Acetylsalicylic acid.Approved, Nutraceutical, Vet Approved
FondaparinuxAcetylsalicylic acid may increase the anticoagulant activities of Fondaparinux.Approved, Investigational
Fondaparinux sodiumAcetylsalicylic acid may increase the anticoagulant activities of Fondaparinux sodium.Approved, Investigational
ForasartanThe risk or severity of adverse effects can be increased when Forasartan is combined with Acetylsalicylic acid.Experimental
FormestaneThe risk or severity of adverse effects can be increased when Acetylsalicylic acid is combined with Formestane.Approved, Investigational, Withdrawn
FosinoprilThe therapeutic efficacy of Fosinopril can be decreased when used in combination with Acetylsalicylic acid.Approved
FosphenytoinThe metabolism of Acetylsalicylic acid can be increased when combined with Fosphenytoin.Approved, Investigational
FramycetinAcetylsalicylic acid may decrease the excretion rate of Framycetin which could result in a higher serum level.Approved
FurosemideThe therapeutic efficacy of Furosemide can be decreased when used in combination with Acetylsalicylic acid.Approved, Vet Approved
GabexateAcetylsalicylic acid may increase the anticoagulant activities of Gabexate.Investigational
GarenoxacinAcetylsalicylic acid may increase the neuroexcitatory activities of Garenoxacin.Investigational
GatifloxacinAcetylsalicylic acid may increase the neuroexcitatory activities of Gatifloxacin.Approved, Investigational
GemeprostThe therapeutic efficacy of Gemeprost can be decreased when used in combination with Acetylsalicylic acid.Approved, Withdrawn
GemfibrozilThe metabolism of Acetylsalicylic acid can be decreased when combined with Gemfibrozil.Approved
GemifloxacinAcetylsalicylic acid may increase the neuroexcitatory activities of Gemifloxacin.Approved, Investigational
GeneticinAcetylsalicylic acid may decrease the excretion rate of Geneticin which could result in a higher serum level.Experimental
GenisteinAcetylsalicylic acid may increase the thrombogenic activities of Genistein.Investigational
GentamicinAcetylsalicylic acid may decrease the excretion rate of Gentamicin which could result in a higher serum level.Approved, Vet Approved
GENTAMICIN C1AAcetylsalicylic acid may decrease the excretion rate of GENTAMICIN C1A which could result in a higher serum level.Experimental
Ginkgo bilobaGinkgo biloba may increase the anticoagulant activities of Acetylsalicylic acid.Approved, Investigational, Nutraceutical
GliclazideAcetylsalicylic acid may increase the hypoglycemic activities of Gliclazide.Approved
GlimepirideAcetylsalicylic acid may increase the hypoglycemic activities of Glimepiride.Approved
GlipizideAcetylsalicylic acid may increase the hypoglycemic activities of Glipizide.Approved, Investigational
GlucosamineGlucosamine may increase the antiplatelet activities of Acetylsalicylic acid.Approved, Investigational
GlyburideAcetylsalicylic acid may increase the hypoglycemic activities of Glyburide.Approved
GrepafloxacinAcetylsalicylic acid may increase the neuroexcitatory activities of Grepafloxacin.Approved, Investigational, Withdrawn
GuacetisalThe risk or severity of adverse effects can be increased when Guacetisal is combined with Acetylsalicylic acid.Experimental
HalcinonideThe risk or severity of adverse effects can be increased when Acetylsalicylic acid is combined with Halcinonide.Approved, Investigational, Withdrawn
HaloperidolThe risk or severity of adverse effects can be increased when Acetylsalicylic acid is combined with Haloperidol.Approved
HE3286The risk or severity of adverse effects can be increased when Acetylsalicylic acid is combined with HE3286.Investigational
Hemoglobin crosfumarilThe risk or severity of adverse effects can be increased when Acetylsalicylic acid is combined with Hemoglobin crosfumaril.Experimental
HeparinAcetylsalicylic acid may increase the anticoagulant activities of Heparin.Approved, Investigational
HexestrolAcetylsalicylic acid may increase the thrombogenic activities of Hexestrol.Withdrawn
HigenamineThe risk or severity of adverse effects can be increased when Higenamine is combined with Acetylsalicylic acid.Investigational
HyaluronidaseThe therapeutic efficacy of Hyaluronidase can be decreased when used in combination with Acetylsalicylic acid.Approved, Investigational
HydralazineAcetylsalicylic acid may decrease the antihypertensive activities of Hydralazine.Approved
HydrochlorothiazideThe therapeutic efficacy of Hydrochlorothiazide can be decreased when used in combination with Acetylsalicylic acid.Approved, Vet Approved
HydrocortisoneThe risk or severity of adverse effects can be increased when Acetylsalicylic acid is combined with Hydrocortisone.Approved, Vet Approved
HydroflumethiazideThe therapeutic efficacy of Hydroflumethiazide can be decreased when used in combination with Acetylsalicylic acid.Approved, Investigational
HydroxytyrosolThe risk or severity of adverse effects can be increased when Hydroxytyrosol is combined with Acetylsalicylic acid.Investigational
Hygromycin BAcetylsalicylic acid may decrease the excretion rate of Hygromycin B which could result in a higher serum level.Vet Approved
IbandronateThe risk or severity of adverse effects can be increased when Acetylsalicylic acid is combined with Ibandronate.Approved, Investigational
Ibritumomab tiuxetanThe risk or severity of adverse effects can be increased when Acetylsalicylic acid is combined with Ibritumomab tiuxetan.Approved, Investigational
IbrutinibThe risk or severity of adverse effects can be increased when Ibrutinib is combined with Acetylsalicylic acid.Approved
IbudilastThe risk or severity of adverse effects can be increased when Ibudilast is combined with Acetylsalicylic acid.Approved, Investigational
IbuproxamThe risk or severity of adverse effects can be increased when Ibuproxam is combined with Acetylsalicylic acid.Withdrawn
IcatibantThe risk or severity of adverse effects can be increased when Icatibant is combined with Acetylsalicylic acid.Approved, Investigational
Icosapent ethylThe risk or severity of adverse effects can be increased when Icosapent ethyl is combined with Acetylsalicylic acid.Approved, Investigational, Nutraceutical
IdraparinuxAcetylsalicylic acid may increase the anticoagulant activities of Idraparinux.Investigational
IfenprodilThe risk or severity of adverse effects can be increased when Ifenprodil is combined with Acetylsalicylic acid.Approved, Investigational, Withdrawn
IfetrobanThe risk or severity of adverse effects can be increased when Ifetroban is combined with Acetylsalicylic acid.Investigational
IloprostThe risk or severity of adverse effects can be increased when Iloprost is combined with Acetylsalicylic acid.Approved, Investigational
ImidaprilThe therapeutic efficacy of Imidapril can be decreased when used in combination with Acetylsalicylic acid.Investigational
Imidazole salicylateThe risk or severity of adverse effects can be increased when Imidazole salicylate is combined with Acetylsalicylic acid.Experimental
IndalpineIndalpine may increase the antiplatelet activities of Acetylsalicylic acid.Investigational, Withdrawn
IndapamideThe therapeutic efficacy of Indapamide can be decreased when used in combination with Acetylsalicylic acid.Approved
IndenololAcetylsalicylic acid may decrease the antihypertensive activities of Indenolol.Withdrawn
IndinavirThe metabolism of Acetylsalicylic acid can be decreased when combined with Indinavir.Approved
IndobufenThe risk or severity of adverse effects can be increased when Indobufen is combined with Acetylsalicylic acid.Investigational
IndoprofenThe risk or severity of adverse effects can be increased when Indoprofen is combined with Acetylsalicylic acid.Withdrawn
Insulin AspartAcetylsalicylic acid may increase the hypoglycemic activities of Insulin Aspart.Approved
Insulin DetemirAcetylsalicylic acid may increase the hypoglycemic activities of Insulin Detemir.Approved
Insulin GlargineAcetylsalicylic acid may increase the hypoglycemic activities of Insulin Glargine.Approved
Insulin GlulisineAcetylsalicylic acid may increase the hypoglycemic activities of Insulin Glulisine.Approved
Insulin HumanAcetylsalicylic acid may increase the hypoglycemic activities of Insulin Human.Approved, Investigational
Insulin LisproAcetylsalicylic acid may increase the hypoglycemic activities of Insulin Lispro.Approved
IrbesartanThe metabolism of Acetylsalicylic acid can be decreased when combined with Irbesartan.Approved, Investigational
IsavuconazoleThe serum concentration of Acetylsalicylic acid can be increased when it is combined with Isavuconazole.Approved, Investigational
IsepamicinAcetylsalicylic acid may decrease the excretion rate of Isepamicin which could result in a higher serum level.Experimental
IsoxicamThe risk or severity of adverse effects can be increased when Isoxicam is combined with Acetylsalicylic acid.Withdrawn
IstaroximeThe risk or severity of adverse effects can be increased when Acetylsalicylic acid is combined with Istaroxime.Investigational
KanamycinAcetylsalicylic acid may decrease the excretion rate of Kanamycin which could result in a higher serum level.Approved, Investigational, Vet Approved
KebuzoneThe risk or severity of adverse effects can be increased when Kebuzone is combined with Acetylsalicylic acid.Experimental
KetanserinThe risk or severity of adverse effects can be increased when Ketanserin is combined with Acetylsalicylic acid.Investigational
KetoconazoleThe metabolism of Acetylsalicylic acid can be decreased when combined with Ketoconazole.Approved, Investigational
KetorolacThe risk or severity of adverse effects can be increased when Ketorolac is combined with Acetylsalicylic acid.Approved
LabetalolAcetylsalicylic acid may decrease the antihypertensive activities of Labetalol.Approved
LandiololAcetylsalicylic acid may decrease the antihypertensive activities of Landiolol.Investigational
LapatinibThe metabolism of Acetylsalicylic acid can be decreased when combined with Lapatinib.Approved, Investigational
LatanoprostThe therapeutic efficacy of Latanoprost can be decreased when used in combination with Acetylsalicylic acid.Approved, Investigational
Latanoprostene BunodThe therapeutic efficacy of Latanoprostene Bunod can be decreased when used in combination with Acetylsalicylic acid.Approved, Investigational
LeflunomideThe risk or severity of adverse effects can be increased when Leflunomide is combined with Acetylsalicylic acid.Approved, Investigational
LepirudinAcetylsalicylic acid may increase the anticoagulant activities of Lepirudin.Approved
LetaxabanAcetylsalicylic acid may increase the anticoagulant activities of Letaxaban.Investigational
LevobetaxololAcetylsalicylic acid may decrease the antihypertensive activities of Levobetaxolol.Approved, Investigational
LevobunololAcetylsalicylic acid may decrease the antihypertensive activities of Levobunolol.Approved
LevofloxacinAcetylsalicylic acid may increase the neuroexcitatory activities of Levofloxacin.Approved, Investigational
LevomilnacipranLevomilnacipran may increase the antiplatelet activities of Acetylsalicylic acid.Approved, Investigational
LimaprostThe risk or severity of adverse effects can be increased when Limaprost is combined with Acetylsalicylic acid.Approved, Investigational
LinsidomineThe risk or severity of adverse effects can be increased when Linsidomine is combined with Acetylsalicylic acid.Experimental
LiraglutideAcetylsalicylic acid may increase the hypoglycemic activities of Liraglutide.Approved
LisinoprilThe therapeutic efficacy of Lisinopril can be decreased when used in combination with Acetylsalicylic acid.Approved, Investigational
LisofyllineThe risk or severity of adverse effects can be increased when Lisofylline is combined with Acetylsalicylic acid.Investigational
LithiumThe serum concentration of Lithium can be increased when it is combined with Acetylsalicylic acid.Approved
LobeglitazoneThe metabolism of Acetylsalicylic acid can be decreased when combined with Lobeglitazone.Approved, Investigational
LomefloxacinAcetylsalicylic acid may increase the neuroexcitatory activities of Lomefloxacin.Approved, Investigational
LonazolacThe risk or severity of adverse effects can be increased when Lonazolac is combined with Acetylsalicylic acid.Experimental
LosartanThe metabolism of Acetylsalicylic acid can be decreased when combined with Losartan.Approved
LoteprednolThe risk or severity of adverse effects can be increased when Acetylsalicylic acid is combined with Loteprednol.Approved
LovastatinThe metabolism of Acetylsalicylic acid can be decreased when combined with Lovastatin.Approved, Investigational
LoxoprofenThe risk or severity of adverse effects can be increased when Loxoprofen is combined with Acetylsalicylic acid.Approved, Investigational
LubiprostoneThe therapeutic efficacy of Lubiprostone can be decreased when used in combination with Acetylsalicylic acid.Approved, Investigational
LumacaftorThe serum concentration of Acetylsalicylic acid can be increased when it is combined with Lumacaftor.Approved
LumiracoxibThe risk or severity of adverse effects can be increased when Acetylsalicylic acid is combined with Lumiracoxib.Approved, Investigational
LuprostiolThe therapeutic efficacy of Luprostiol can be decreased when used in combination with Acetylsalicylic acid.Vet Approved
ManidipineThe metabolism of Acetylsalicylic acid can be decreased when combined with Manidipine.Approved, Investigational
MasoprocolThe risk or severity of adverse effects can be increased when Masoprocol is combined with Acetylsalicylic acid.Approved, Investigational
ME-609The risk or severity of adverse effects can be increased when Acetylsalicylic acid is combined with ME-609.Investigational
MecaserminAcetylsalicylic acid may increase the hypoglycemic activities of Mecasermin.Approved, Investigational
MedrysoneThe risk or severity of adverse effects can be increased when Acetylsalicylic acid is combined with Medrysone.Approved
MelagatranAcetylsalicylic acid may increase the anticoagulant activities of Melagatran.Experimental
MelengestrolThe risk or severity of adverse effects can be increased when Acetylsalicylic acid is combined with Melengestrol.Vet Approved
MepindololAcetylsalicylic acid may decrease the antihypertensive activities of Mepindolol.Experimental
MestranolAcetylsalicylic acid may increase the thrombogenic activities of Mestranol.Approved
MetamizoleThe risk or severity of adverse effects can be increased when Metamizole is combined with Acetylsalicylic acid.Approved, Investigational, Withdrawn
MetforminAcetylsalicylic acid may increase the hypoglycemic activities of Metformin.Approved
MethallenestrilAcetylsalicylic acid may increase the thrombogenic activities of Methallenestril.Experimental
MethazolamideThe risk or severity of adverse effects can be increased when Acetylsalicylic acid is combined with Methazolamide.Approved
MethotrexateThe serum concentration of Methotrexate can be increased when it is combined with Acetylsalicylic acid.Approved
MethyclothiazideThe therapeutic efficacy of Methyclothiazide can be decreased when used in combination with Acetylsalicylic acid.Approved
Methyl salicylateThe risk or severity of adverse effects can be increased when Acetylsalicylic acid is combined with Methyl salicylate.Approved, Vet Approved
MethylprednisoloneThe risk or severity of adverse effects can be increased when Acetylsalicylic acid is combined with Methylprednisolone.Approved, Vet Approved
MetipranololAcetylsalicylic acid may decrease the antihypertensive activities of Metipranolol.Approved
MetolazoneThe therapeutic efficacy of Metolazone can be decreased when used in combination with Acetylsalicylic acid.Approved
MetoprololAcetylsalicylic acid may decrease the antihypertensive activities of Metoprolol.Approved, Investigational
MicronomicinAcetylsalicylic acid may decrease the excretion rate of Micronomicin which could result in a higher serum level.Experimental
MidostaurinThe metabolism of Acetylsalicylic acid can be decreased when combined with Midostaurin.Approved, Investigational
MifamurtideThe therapeutic efficacy of Mifamurtide can be decreased when used in combination with Acetylsalicylic acid.Approved, Experimental
MifepristoneThe serum concentration of Acetylsalicylic acid can be increased when it is combined with Mifepristone.Approved, Investigational
MiglitolAcetylsalicylic acid may increase the hypoglycemic activities of Miglitol.Approved
MilnacipranMilnacipran may increase the antiplatelet activities of Acetylsalicylic acid.Approved, Investigational
MilrinoneThe risk or severity of adverse effects can be increased when Milrinone is combined with Acetylsalicylic acid.Approved
MisoprostolThe therapeutic efficacy of Misoprostol can be decreased when used in combination with Acetylsalicylic acid.Approved
MizoribineThe risk or severity of adverse effects can be increased when Mizoribine is combined with Acetylsalicylic acid.Investigational
MoexiprilThe therapeutic efficacy of Moexipril can be decreased when used in combination with Acetylsalicylic acid.Approved
MofebutazoneThe risk or severity of adverse effects can be increased when Mofebutazone is combined with Acetylsalicylic acid.Experimental
MometasoneThe risk or severity of adverse effects can be increased when Acetylsalicylic acid is combined with Mometasone.Approved, Vet Approved
MorniflumateThe risk or severity of adverse effects can be increased when Morniflumate is combined with Acetylsalicylic acid.Approved
MoxestrolAcetylsalicylic acid may increase the thrombogenic activities of Moxestrol.Experimental
MoxifloxacinAcetylsalicylic acid may increase the neuroexcitatory activities of Moxifloxacin.Approved, Investigational
Mycophenolate mofetilThe risk or severity of adverse effects can be increased when Mycophenolate mofetil is combined with Acetylsalicylic acid.Approved, Investigational
Mycophenolic acidThe risk or severity of adverse effects can be increased when Mycophenolic acid is combined with Acetylsalicylic acid.Approved
NabiloneThe metabolism of Acetylsalicylic acid can be decreased when combined with Nabilone.Approved, Investigational
NabumetoneThe risk or severity of adverse effects can be increased when Acetylsalicylic acid is combined with Nabumetone.Approved
NadololAcetylsalicylic acid may decrease the antihypertensive activities of Nadolol.Approved
NadroparinAcetylsalicylic acid may increase the anticoagulant activities of Nadroparin.Approved, Investigational
NafamostatThe risk or severity of adverse effects can be increased when Nafamostat is combined with Acetylsalicylic acid.Approved, Investigational
NaftifineThe risk or severity of adverse effects can be increased when Naftifine is combined with Acetylsalicylic acid.Approved
NaftopidilThe risk or severity of adverse effects can be increased when Naftopidil is combined with Acetylsalicylic acid.Investigational
Nalidixic AcidAcetylsalicylic acid may increase the neuroexcitatory activities of Nalidixic Acid.Approved, Investigational
NateglinideAcetylsalicylic acid may increase the hypoglycemic activities of Nateglinide.Approved, Investigational
NCX 1022The risk or severity of adverse effects can be increased when Acetylsalicylic acid is combined with NCX 1022.Investigational
NeamineAcetylsalicylic acid may decrease the excretion rate of Neamine which could result in a higher serum level.Experimental
NebivololAcetylsalicylic acid may decrease the antihypertensive activities of Nebivolol.Approved, Investigational
NefazodoneNefazodone may increase the antiplatelet activities of Acetylsalicylic acid.Approved, Withdrawn
NemonoxacinAcetylsalicylic acid may increase the neuroexcitatory activities of Nemonoxacin.Investigational
NeomycinAcetylsalicylic acid may decrease the excretion rate of Neomycin which could result in a higher serum level.Approved, Vet Approved
NetilmicinAcetylsalicylic acid may decrease the excretion rate of Netilmicin which could result in a higher serum level.Approved, Investigational
NicardipineThe metabolism of Acetylsalicylic acid can be decreased when combined with Nicardipine.Approved, Investigational
NicorandilThe risk or severity of adverse effects can be increased when Acetylsalicylic acid is combined with Nicorandil.Approved, Investigational
NifenazoneThe risk or severity of adverse effects can be increased when Nifenazone is combined with Acetylsalicylic acid.Experimental
NilotinibThe metabolism of Acetylsalicylic acid can be decreased when combined with Nilotinib.Approved, Investigational
NitroaspirinThe risk or severity of adverse effects can be increased when Nitroaspirin is combined with Acetylsalicylic acid.Investigational
NorfloxacinAcetylsalicylic acid may increase the neuroexcitatory activities of Norfloxacin.Approved
ObinutuzumabThe risk or severity of adverse effects can be increased when Acetylsalicylic acid is combined with Obinutuzumab.Approved, Investigational
OfloxacinAcetylsalicylic acid may increase the neuroexcitatory activities of Ofloxacin.Approved
Oleoyl-estroneThe risk or severity of adverse effects can be increased when Acetylsalicylic acid is combined with Oleoyl-estrone.Investigational
OlmesartanThe risk or severity of adverse effects can be increased when Olmesartan is combined with Acetylsalicylic acid.Approved, Investigational
OlopatadineThe risk or severity of adverse effects can be increased when Olopatadine is combined with Acetylsalicylic acid.Approved
OlsalazineThe risk or severity of adverse effects can be increased when Olsalazine is combined with Acetylsalicylic acid.Approved
Omacetaxine mepesuccinateThe risk or severity of adverse effects can be increased when Acetylsalicylic acid is combined with Omacetaxine mepesuccinate.Approved, Investigational
OmapatrilatThe therapeutic efficacy of Omapatrilat can be decreased when used in combination with Acetylsalicylic acid.Investigational
Omega-3 fatty acidsOmega-3 fatty acids may increase the antiplatelet activities of Acetylsalicylic acid.Approved, Nutraceutical
OmeprazoleThe metabolism of Acetylsalicylic acid can be decreased when combined with Omeprazole.Approved, Investigational, Vet Approved
OrgoteinThe risk or severity of adverse effects can be increased when Orgotein is combined with Acetylsalicylic acid.Vet Approved
OtamixabanAcetylsalicylic acid may increase the anticoagulant activities of Otamixaban.Investigational
Oxolinic acidAcetylsalicylic acid may increase the neuroexcitatory activities of Oxolinic acid.Experimental
OxprenololAcetylsalicylic acid may decrease the antihypertensive activities of Oxprenolol.Approved
OxyphenbutazoneThe risk or severity of adverse effects can be increased when Oxyphenbutazone is combined with Acetylsalicylic acid.Approved, Withdrawn
OzagrelThe risk or severity of adverse effects can be increased when Acetylsalicylic acid is combined with Ozagrel.Investigational
PalmidrolThe risk or severity of adverse effects can be increased when Palmidrol is combined with Acetylsalicylic acid.Experimental, Nutraceutical
PamidronateThe risk or severity of adverse effects can be increased when Acetylsalicylic acid is combined with Pamidronate.Approved
ParamethasoneThe risk or severity of adverse effects can be increased when Acetylsalicylic acid is combined with Paramethasone.Approved
ParecoxibThe risk or severity of adverse effects can be increased when Acetylsalicylic acid is combined with Parecoxib.Approved
ParnaparinThe risk or severity of adverse effects can be increased when Acetylsalicylic acid is combined with Parnaparin.Approved, Investigational
ParomomycinAcetylsalicylic acid may decrease the excretion rate of Paromomycin which could result in a higher serum level.Approved, Investigational
ParoxetineParoxetine may increase the antiplatelet activities of Acetylsalicylic acid.Approved, Investigational
ParthenolideThe risk or severity of adverse effects can be increased when Parthenolide is combined with Acetylsalicylic acid.Approved, Investigational
PazufloxacinAcetylsalicylic acid may increase the neuroexcitatory activities of Pazufloxacin.Investigational
PefloxacinAcetylsalicylic acid may increase the neuroexcitatory activities of Pefloxacin.Approved
PenbutololAcetylsalicylic acid may decrease the antihypertensive activities of Penbutolol.Approved, Investigational
Pentaerythritol TetranitrateAcetylsalicylic acid may increase the anticoagulant activities of Pentaerythritol Tetranitrate.Approved
PentamidineAcetylsalicylic acid may increase the hypoglycemic activities of Pentamidine.Approved, Investigational
Pentosan PolysulfateThe risk or severity of adverse effects can be increased when Pentosan Polysulfate is combined with Acetylsalicylic acid.Approved
PentoxifyllinePentoxifylline may increase the antiplatelet activities of Acetylsalicylic acid.Approved, Investigational
PerindoprilThe therapeutic efficacy of Perindopril can be decreased when used in combination with Acetylsalicylic acid.Approved
PhenindioneAcetylsalicylic acid may increase the anticoagulant activities of Phenindione.Approved, Investigational
PhenobarbitalThe metabolism of Acetylsalicylic acid can be increased when combined with Phenobarbital.Approved, Investigational
PhenprocoumonAcetylsalicylic acid may increase the anticoagulant activities of Phenprocoumon.Approved, Investigational
Phenyl aminosalicylateThe risk or severity of adverse effects can be increased when Acetylsalicylic acid is combined with Phenyl aminosalicylate.Approved
PhenytoinThe metabolism of Acetylsalicylic acid can be increased when combined with Phenytoin.Approved, Vet Approved
PicotamideThe risk or severity of adverse effects can be increased when Picotamide is combined with Acetylsalicylic acid.Experimental
PimecrolimusThe risk or severity of adverse effects can be increased when Pimecrolimus is combined with Acetylsalicylic acid.Approved, Investigational
PindololAcetylsalicylic acid may decrease the antihypertensive activities of Pindolol.Approved, Investigational
PioglitazoneThe metabolism of Acetylsalicylic acid can be decreased when combined with Pioglitazone.Approved, Investigational
Pipemidic acidAcetylsalicylic acid may increase the neuroexcitatory activities of Pipemidic acid.Experimental
PiretanideThe therapeutic efficacy of Piretanide can be decreased when used in combination with Acetylsalicylic acid.Approved
PirfenidoneThe risk or severity of adverse effects can be increased when Pirfenidone is combined with Acetylsalicylic acid.Approved, Investigational
Piromidic acidAcetylsalicylic acid may increase the neuroexcitatory activities of Piromidic acid.Experimental
PirprofenThe risk or severity of adverse effects can be increased when Pirprofen is combined with Acetylsalicylic acid.Experimental
PitolisantThe serum concentration of Acetylsalicylic acid can be decreased when it is combined with Pitolisant.Approved, Investigational
Platelet Activating FactorAcetylsalicylic acid may decrease the antihypertensive activities of Platelet Activating Factor.Experimental
PlazomicinAcetylsalicylic acid may decrease the excretion rate of Plazomicin which could result in a higher serum level.Investigational
Polyestradiol phosphateAcetylsalicylic acid may increase the thrombogenic activities of Polyestradiol phosphate.Approved
PolythiazideThe therapeutic efficacy of Polythiazide can be decreased when used in combination with Acetylsalicylic acid.Approved
Potassium CitrateAcetylsalicylic acid may increase the anticoagulant activities of Potassium Citrate.Approved, Investigational, Vet Approved
PractololAcetylsalicylic acid may decrease the antihypertensive activities of Practolol.Approved
PralatrexateThe serum concentration of Pralatrexate can be increased when it is combined with Acetylsalicylic acid.Approved, Investigational
PramlintideAcetylsalicylic acid may increase the hypoglycemic activities of Pramlintide.Approved, Investigational
PranoprofenThe risk or severity of adverse effects can be increased when Pranoprofen is combined with Acetylsalicylic acid.Experimental, Investigational
PrasteroneThe risk or severity of adverse effects can be increased when Acetylsalicylic acid is combined with Prasterone.Approved, Investigational, Nutraceutical
Prasterone sulfateThe risk or severity of adverse effects can be increased when Acetylsalicylic acid is combined with Prasterone sulfate.Investigational
PrasugrelThe risk or severity of adverse effects can be increased when Prasugrel is combined with Acetylsalicylic acid.Approved
PrednicarbateThe risk or severity of adverse effects can be increased when Acetylsalicylic acid is combined with Prednicarbate.Approved, Investigational
PrednisoloneThe risk or severity of adverse effects can be increased when Acetylsalicylic acid is combined with Prednisolone.Approved, Vet Approved
PrednisoneThe risk or severity of adverse effects can be increased when Acetylsalicylic acid is combined with Prednisone.Approved, Vet Approved
PregnenoloneThe risk or severity of adverse effects can be increased when Acetylsalicylic acid is combined with Pregnenolone.Approved, Experimental, Investigational
PrimidoneThe metabolism of Acetylsalicylic acid can be increased when combined with Primidone.Approved, Vet Approved
ProbenecidThe therapeutic efficacy of Probenecid can be decreased when used in combination with Acetylsalicylic acid.Approved, Investigational
ProglumetacinThe risk or severity of adverse effects can be increased when Proglumetacin is combined with Acetylsalicylic acid.Experimental
PromestrieneAcetylsalicylic acid may increase the thrombogenic activities of Promestriene.Investigational
PropacetamolThe risk or severity of adverse effects can be increased when Propacetamol is combined with Acetylsalicylic acid.Approved, Investigational
PropafenoneAcetylsalicylic acid may decrease the antihypertensive activities of Propafenone.Approved
PropranololAcetylsalicylic acid may decrease the antihypertensive activities of Propranolol.Approved, Investigational
PropyphenazoneThe risk or severity of adverse effects can be increased when Propyphenazone is combined with Acetylsalicylic acid.Experimental
ProquazoneThe risk or severity of adverse effects can be increased when Proquazone is combined with Acetylsalicylic acid.Experimental
Prostaglandin B2The therapeutic efficacy of Prostaglandin B2 can be decreased when used in combination with Acetylsalicylic acid.Experimental
Prostaglandin G2The therapeutic efficacy of Prostaglandin G2 can be decreased when used in combination with Acetylsalicylic acid.Experimental
ProstaleneThe therapeutic efficacy of Prostalene can be decreased when used in combination with Acetylsalicylic acid.Vet Approved
Protein CAcetylsalicylic acid may increase the anticoagulant activities of Protein C.Approved
Protein S humanAcetylsalicylic acid may increase the anticoagulant activities of Protein S human.Approved
ProtocatechualdehydeAcetylsalicylic acid may increase the anticoagulant activities of Protocatechualdehyde.Approved
PrulifloxacinAcetylsalicylic acid may increase the neuroexcitatory activities of Prulifloxacin.Investigational
PTC299The risk or severity of adverse effects can be increased when PTC299 is combined with Acetylsalicylic acid.Investigational
PuromycinAcetylsalicylic acid may decrease the excretion rate of Puromycin which could result in a higher serum level.Experimental
PyrimethamineThe metabolism of Acetylsalicylic acid can be decreased when combined with Pyrimethamine.Approved, Investigational, Vet Approved
QuinaprilThe therapeutic efficacy of Quinapril can be decreased when used in combination with Acetylsalicylic acid.Approved, Investigational
QuinestrolAcetylsalicylic acid may increase the thrombogenic activities of Quinestrol.Approved
QuinethazoneThe therapeutic efficacy of Quinethazone can be decreased when used in combination with Acetylsalicylic acid.Approved
QuinineThe metabolism of Acetylsalicylic acid can be decreased when combined with Quinine.Approved
RabeprazoleThe metabolism of Acetylsalicylic acid can be decreased when combined with Rabeprazole.Approved, Investigational
RamatrobanThe risk or severity of adverse effects can be increased when Ramatroban is combined with Acetylsalicylic acid.Investigational
RamiprilThe therapeutic efficacy of Ramipril can be decreased when used in combination with Acetylsalicylic acid.Approved
RanolazineThe serum concentration of Acetylsalicylic acid can be increased when it is combined with Ranolazine.Approved, Investigational
RelcovaptanThe risk or severity of adverse effects can be increased when Relcovaptan is combined with Acetylsalicylic acid.Investigational
RepaglinideAcetylsalicylic acid may increase the hypoglycemic activities of Repaglinide.Approved, Investigational
RescinnamineThe therapeutic efficacy of Rescinnamine can be decreased when used in combination with Acetylsalicylic acid.Approved
ReteplaseThe risk or severity of adverse effects can be increased when Acetylsalicylic acid is combined with Reteplase.Approved, Investigational
ReviparinAcetylsalicylic acid may increase the anticoagulant activities of Reviparin.Approved, Investigational
RibostamycinAcetylsalicylic acid may decrease the excretion rate of Ribostamycin which could result in a higher serum level.Approved, Investigational
RidogrelThe risk or severity of adverse effects can be increased when Ridogrel is combined with Acetylsalicylic acid.Approved
RifampicinThe metabolism of Acetylsalicylic acid can be increased when combined with Rifampicin.Approved
RifapentineThe metabolism of Acetylsalicylic acid can be increased when combined with Rifapentine.Approved, Investigational
RimexoloneThe risk or severity of adverse effects can be increased when Acetylsalicylic acid is combined with Rimexolone.Approved
RisedronateThe risk or severity of adverse effects can be increased when Acetylsalicylic acid is combined with Risedronate.Approved, Investigational
RivaroxabanAcetylsalicylic acid may increase the anticoagulant activities of Rivaroxaban.Approved
RofecoxibThe risk or severity of adverse effects can be increased when Acetylsalicylic acid is combined with Rofecoxib.Approved, Investigational, Withdrawn
RosiglitazoneThe risk or severity of adverse effects can be increased when Acetylsalicylic acid is combined with Rosiglitazone.Approved, Investigational
RosoxacinAcetylsalicylic acid may increase the neuroexcitatory activities of Rosoxacin.Approved, Investigational
RucaparibThe metabolism of Acetylsalicylic acid can be decreased when combined with Rucaparib.Approved, Investigational
RufloxacinAcetylsalicylic acid may increase the neuroexcitatory activities of Rufloxacin.Experimental
SacubitrilThe risk or severity of adverse effects can be increased when Sacubitril is combined with Acetylsalicylic acid.Approved
SalicylamideThe risk or severity of adverse effects can be increased when Salicylamide is combined with Acetylsalicylic acid.Approved
SaprisartanThe risk or severity of adverse effects can be increased when Saprisartan is combined with Acetylsalicylic acid.Experimental
SaralasinThe risk or severity of adverse effects can be increased when Saralasin is combined with Acetylsalicylic acid.Investigational
SarilumabSarilumab may increase the immunosuppressive activities of Acetylsalicylic acid.Approved, Investigational
SarpogrelateThe risk or severity of adverse effects can be increased when Sarpogrelate is combined with Acetylsalicylic acid.Investigational
SaruplaseThe risk or severity of adverse effects can be increased when Acetylsalicylic acid is combined with Saruplase.Experimental
SaxagliptinAcetylsalicylic acid may increase the hypoglycemic activities of Saxagliptin.Approved
SecobarbitalThe metabolism of Acetylsalicylic acid can be increased when combined with Secobarbital.Approved, Vet Approved
SecoisolariciresinolAcetylsalicylic acid may increase the thrombogenic activities of Secoisolariciresinol.Investigational
SelexipagThe risk or severity of adverse effects can be increased when Acetylsalicylic acid is combined with Selexipag.Approved
SemapimodThe risk or severity of adverse effects can be increased when Semapimod is combined with Acetylsalicylic acid.Investigational
SeratrodastThe risk or severity of adverse effects can be increased when Seratrodast is combined with Acetylsalicylic acid.Approved
SerrapeptaseThe risk or severity of adverse effects can be increased when Serrapeptase is combined with Acetylsalicylic acid.Investigational
SertralineSertraline may increase the antiplatelet activities of Acetylsalicylic acid.Approved
SevofluraneThe risk or severity of adverse effects can be increased when Sevoflurane is combined with Acetylsalicylic acid.Approved, Vet Approved
SildenafilThe metabolism of Acetylsalicylic acid can be decreased when combined with Sildenafil.Approved, Investigational
SisomicinAcetylsalicylic acid may decrease the excretion rate of Sisomicin which could result in a higher serum level.Investigational
SitafloxacinAcetylsalicylic acid may increase the neuroexcitatory activities of Sitafloxacin.Experimental, Investigational
SitagliptinAcetylsalicylic acid may increase the hypoglycemic activities of Sitagliptin.Approved, Investigational
Sodium CitrateAcetylsalicylic acid may increase the anticoagulant activities of Sodium Citrate.Approved, Investigational
Sodium phosphateSodium phosphate may increase the nephrotoxic activities of Acetylsalicylic acid.Approved
SorafenibThe metabolism of Acetylsalicylic acid can be decreased when combined with Sorafenib.Approved, Investigational
SotalolAcetylsalicylic acid may decrease the antihypertensive activities of Sotalol.Approved
SparfloxacinAcetylsalicylic acid may increase the neuroexcitatory activities of Sparfloxacin.Approved, Investigational
SpiraprilThe therapeutic efficacy of Spirapril can be decreased when used in combination with Acetylsalicylic acid.Approved
SpironolactoneAcetylsalicylic acid may decrease the antihypertensive activities of Spironolactone.Approved
SRT501The risk or severity of adverse effects can be increased when SRT501 is combined with Acetylsalicylic acid.Investigational
StreptokinaseThe risk or severity of adverse effects can be increased when Acetylsalicylic acid is combined with Streptokinase.Approved, Investigational
StreptomycinAcetylsalicylic acid may decrease the excretion rate of Streptomycin which could result in a higher serum level.Approved, Vet Approved
SulfadiazineThe metabolism of Acetylsalicylic acid can be decreased when combined with Sulfadiazine.Approved, Investigational, Vet Approved
SulfamethoxazoleThe metabolism of Acetylsalicylic acid can be decreased when combined with Sulfamethoxazole.Approved
SulfisoxazoleThe metabolism of Acetylsalicylic acid can be decreased when combined with Sulfisoxazole.Approved, Vet Approved
SulodexideAcetylsalicylic acid may increase the anticoagulant activities of Sulodexide.Approved, Investigational
SulprostoneThe therapeutic efficacy of Sulprostone can be decreased when used in combination with Acetylsalicylic acid.Investigational
SunitinibAcetylsalicylic acid may increase the hypoglycemic activities of Sunitinib.Approved, Investigational
SuxibuzoneThe risk or severity of adverse effects can be increased when Suxibuzone is combined with Acetylsalicylic acid.Experimental
Synthetic Conjugated Estrogens, AAcetylsalicylic acid may increase the thrombogenic activities of Synthetic Conjugated Estrogens, A.Approved
Synthetic Conjugated Estrogens, BAcetylsalicylic acid may increase the thrombogenic activities of Synthetic Conjugated Estrogens, B.Approved
TacrolimusAcetylsalicylic acid may increase the nephrotoxic activities of Tacrolimus.Approved, Investigational
TafluprostThe therapeutic efficacy of Tafluprost can be decreased when used in combination with Acetylsalicylic acid.Approved
TalinololAcetylsalicylic acid may decrease the antihypertensive activities of Talinolol.Investigational
TalniflumateThe risk or severity of adverse effects can be increased when Acetylsalicylic acid is combined with Talniflumate.Approved
TamoxifenThe metabolism of Acetylsalicylic acid can be decreased when combined with Tamoxifen.Approved
TarenflurbilThe risk or severity of adverse effects can be increased when Tarenflurbil is combined with Acetylsalicylic acid.Investigational
TasosartanThe risk or severity of adverse effects can be increased when Tasosartan is combined with Acetylsalicylic acid.Approved
Technetium Tc-99m etidronateThe risk or severity of adverse effects can be increased when Acetylsalicylic acid is combined with Technetium Tc-99m etidronate.Approved
Technetium Tc-99m medronateThe risk or severity of adverse effects can be increased when Acetylsalicylic acid is combined with Technetium Tc-99m medronate.Approved
TelmisartanThe risk or severity of adverse effects can be increased when Telmisartan is combined with Acetylsalicylic acid.Approved, Investigational
TemafloxacinAcetylsalicylic acid may increase the neuroexcitatory activities of Temafloxacin.Withdrawn
TemocaprilThe therapeutic efficacy of Temocapril can be decreased when used in combination with Acetylsalicylic acid.Experimental, Investigational
TenecteplaseThe risk or severity of adverse effects can be increased when Acetylsalicylic acid is combined with Tenecteplase.Approved
TenidapThe risk or severity of adverse effects can be increased when Tenidap is combined with Acetylsalicylic acid.Experimental
Tenofovir disoproxilThe risk or severity of adverse effects can be increased when Acetylsalicylic acid is combined with Tenofovir disoproxil.Approved, Investigational
TepoxalinThe risk or severity of adverse effects can be increased when Tepoxalin is combined with Acetylsalicylic acid.Vet Approved
TerbutalineAcetylsalicylic acid may decrease the antihypertensive activities of Terbutaline.Approved
TeriflunomideThe risk or severity of adverse effects can be increased when Teriflunomide is combined with Acetylsalicylic acid.Approved
TertatololAcetylsalicylic acid may decrease the antihypertensive activities of Tertatolol.Experimental
TesmilifeneThe risk or severity of adverse effects can be increased when Tesmilifene is combined with Acetylsalicylic acid.Investigational
TiboloneAcetylsalicylic acid may increase the thrombogenic activities of Tibolone.Approved, Investigational
TicagrelorAcetylsalicylic acid may increase the antiplatelet activities of Ticagrelor.Approved
TiclopidineThe risk or severity of adverse effects can be increased when Ticlopidine is combined with Acetylsalicylic acid.Approved
Tiludronic acidThe serum concentration of Tiludronic acid can be decreased when it is combined with Acetylsalicylic acid.Approved, Investigational, Vet Approved
TimololAcetylsalicylic acid may decrease the antihypertensive activities of Timolol.Approved
TinoridineThe risk or severity of adverse effects can be increased when Tinoridine is combined with Acetylsalicylic acid.Investigational
TinzaparinThe risk or severity of adverse effects can be increased when Acetylsalicylic acid is combined with Tinzaparin.Approved
TioclomarolAcetylsalicylic acid may increase the anticoagulant activities of Tioclomarol.Experimental
TipranavirTipranavir may increase the antiplatelet activities of Acetylsalicylic acid.Approved, Investigational
TirofibanThe risk or severity of adverse effects can be increased when Tirofiban is combined with Acetylsalicylic acid.Approved
TixocortolThe risk or severity of adverse effects can be increased when Acetylsalicylic acid is combined with Tixocortol.Approved, Withdrawn
TobramycinAcetylsalicylic acid may decrease the excretion rate of Tobramycin which could result in a higher serum level.Approved, Investigational
TolazamideAcetylsalicylic acid may increase the hypoglycemic activities of Tolazamide.Approved, Investigational
TolbutamideThe metabolism of Acetylsalicylic acid can be decreased when combined with Tolbutamide.Approved, Investigational
Tolfenamic AcidThe risk or severity of adverse effects can be increased when Tolfenamic Acid is combined with Acetylsalicylic acid.Approved, Investigational
TopiroxostatThe metabolism of Acetylsalicylic acid can be decreased when combined with Topiroxostat.Approved, Investigational
TorasemideThe therapeutic efficacy of Torasemide can be decreased when used in combination with Acetylsalicylic acid.Approved
TositumomabThe risk or severity of adverse effects can be increased when Acetylsalicylic acid is combined with Tositumomab.Approved, Investigational
TrandolaprilThe therapeutic efficacy of Trandolapril can be decreased when used in combination with Acetylsalicylic acid.Approved
TranilastThe risk or severity of adverse effects can be increased when Tranilast is combined with Acetylsalicylic acid.Approved, Investigational
TrapidilThe risk or severity of adverse effects can be increased when Trapidil is combined with Acetylsalicylic acid.Approved
TravoprostThe therapeutic efficacy of Travoprost can be decreased when used in combination with Acetylsalicylic acid.Approved
TreprostinilThe risk or severity of adverse effects can be increased when Treprostinil is combined with Acetylsalicylic acid.Approved, Investigational
TriamtereneAcetylsalicylic acid may decrease the antihypertensive activities of Triamterene.Approved
TribenosideThe risk or severity of adverse effects can be increased when Tribenoside is combined with Acetylsalicylic acid.Experimental
TrichlormethiazideThe therapeutic efficacy of Trichlormethiazide can be decreased when used in combination with Acetylsalicylic acid.Approved, Vet Approved
TriflusalThe risk or severity of adverse effects can be increased when Triflusal is combined with Acetylsalicylic acid.Approved, Investigational
TrimethoprimThe metabolism of Acetylsalicylic acid can be decreased when combined with Trimethoprim.Approved, Vet Approved
TriptolideThe risk or severity of adverse effects can be increased when Triptolide is combined with Acetylsalicylic acid.Investigational
TrovafloxacinAcetylsalicylic acid may increase the neuroexcitatory activities of Trovafloxacin.Approved, Investigational, Withdrawn
TroxerutinAcetylsalicylic acid may increase the anticoagulant activities of Troxerutin.Investigational
UlobetasolThe risk or severity of adverse effects can be increased when Acetylsalicylic acid is combined with Ulobetasol.Approved
UnoprostoneThe therapeutic efficacy of Unoprostone can be decreased when used in combination with Acetylsalicylic acid.Approved, Investigational
UrokinaseAcetylsalicylic acid may increase the anticoagulant activities of Urokinase.Approved, Investigational, Withdrawn
ValdecoxibThe risk or severity of adverse effects can be increased when Acetylsalicylic acid is combined with Valdecoxib.Approved, Investigational, Withdrawn
Valproic AcidThe serum concentration of Valproic Acid can be increased when it is combined with Acetylsalicylic acid.Approved, Investigational
ValsartanThe metabolism of Acetylsalicylic acid can be decreased when combined with Valsartan.Approved, Investigational
VancomycinThe serum concentration of Vancomycin can be increased when it is combined with Acetylsalicylic acid.Approved
VemurafenibThe serum concentration of Acetylsalicylic acid can be increased when it is combined with Vemurafenib.Approved
VenlafaxineVenlafaxine may increase the antiplatelet activities of Acetylsalicylic acid.Approved
VerapamilVerapamil may increase the anticoagulant activities of Acetylsalicylic acid.Approved
Vitamin EVitamin E may increase the antiplatelet activities of Acetylsalicylic acid.Approved, Nutraceutical, Vet Approved
VorapaxarThe risk or severity of adverse effects can be increased when Vorapaxar is combined with Acetylsalicylic acid.Approved
VoriconazoleThe metabolism of Acetylsalicylic acid can be decreased when combined with Voriconazole.Approved, Investigational
WarfarinAcetylsalicylic acid may increase the anticoagulant activities of Warfarin.Approved
XimelagatranAcetylsalicylic acid may increase the anticoagulant activities of Ximelagatran.Approved, Investigational, Withdrawn
ZafirlukastThe metabolism of Acetylsalicylic acid can be decreased when combined with Zafirlukast.Approved, Investigational
ZaltoprofenThe risk or severity of adverse effects can be increased when Zaltoprofen is combined with Acetylsalicylic acid.Approved, Investigational
ZeranolAcetylsalicylic acid may increase the thrombogenic activities of Zeranol.Vet Approved
ZileutonThe risk or severity of adverse effects can be increased when Zileuton is combined with Acetylsalicylic acid.Approved, Investigational, Withdrawn
ZimelidineZimelidine may increase the antiplatelet activities of Acetylsalicylic acid.Withdrawn
ZofenoprilThe therapeutic efficacy of Zofenopril can be decreased when used in combination with Acetylsalicylic acid.Experimental
Zoledronic acidThe risk or severity of adverse effects can be increased when Acetylsalicylic acid is combined with Zoledronic acid.Approved
ZomepiracThe risk or severity of adverse effects can be increased when Zomepirac is combined with Acetylsalicylic acid.Withdrawn
Food Interactions
  • Avoid alcohol, alcohol appears to cause a 50 to 100% increases in ASA serum levels.
  • Take with a full glass of water.
  • Take with food to reduce gastric irritation.

References

Synthesis Reference

Marino Gobetti, Guido Vandoni, "Acetylsalicylic acid thioesters, a process for their preparation and pharmaceutical compositions containing them." U.S. Patent US4563443, issued March, 1981.

US4563443
General References
  1. Macdonald S: Aspirin use to be banned in under 16 year olds. BMJ. 2002 Nov 2;325(7371):988. [PubMed:12411346]
  2. Sneader W: The discovery of aspirin: a reappraisal. BMJ. 2000 Dec 23-30;321(7276):1591-4. [PubMed:11124191]
  3. Aukerman G, Knutson D, Miser WF: Management of the acute migraine headache. Am Fam Physician. 2002 Dec 1;66(11):2123-30. [PubMed:12484694]
  4. Authors unspecified: Randomised trial of intravenous streptokinase, oral aspirin, both, or neither among 17,187 cases of suspected acute myocardial infarction: ISIS-2. ISIS-2 (Second International Study of Infarct Survival) Collaborative Group. Lancet. 1988 Aug 13;2(8607):349-60. [PubMed:2899772]
  5. Dorsch MP, Lee JS, Lynch DR, Dunn SP, Rodgers JE, Schwartz T, Colby E, Montague D, Smyth SS: Aspirin resistance in patients with stable coronary artery disease with and without a history of myocardial infarction. Ann Pharmacother. 2007 May;41(5):737-41. Epub 2007 Apr 24. [PubMed:17456544]
External Links
Human Metabolome Database
HMDB0001879
KEGG Drug
D00109
KEGG Compound
C01405
PubChem Compound
2244
PubChem Substance
46505803
ChemSpider
2157
BindingDB
22360
ChEBI
15365
ChEMBL
CHEMBL25
Therapeutic Targets Database
DAP000843
PharmGKB
PA448497
IUPHAR
4139
Guide to Pharmacology
GtP Drug Page
HET
AIN
RxList
RxList Drug Page
Drugs.com
Drugs.com Drug Page
PDRhealth
PDRhealth Drug Page
Wikipedia
Aspirin
ATC Codes
C10BX04 — Simvastatin, acetylsalicylic acid and ramiprilB01AC56 — Acetylsalicylic acid, combinations with proton pump inhibitorsM01BA03 — Acetylsalicylic acid and corticosteroidsN02BA51 — Acetylsalicylic acid, combinations excl. psycholepticsC10BX06 — Atorvastatin, acetylsalicylic acid and ramiprilN02BA71 — Acetylsalicylic acid, combinations with psycholepticsC10BX05 — Rosuvastatin and acetylsalicylic acidN02BA01 — Acetylsalicylic acidB01AC06 — Acetylsalicylic acidC10BX02 — Pravastatin and acetylsalicylic acidA01AD05 — Acetylsalicylic acidC10BX08 — Atorvastatin and acetylsalicylic acidC10BX01 — Simvastatin and acetylsalicylic acid
AHFS Codes
  • 28:08.04.24 — Salicylates
PDB Entries
1oxr / 1tgm / 2qqt / 3gcl / 3iaz / 4nsb
FDA label
Download (889 KB)
MSDS
Download (18.9 KB)

Clinical Trials

Clinical Trials
PhaseStatusPurposeConditionsCount
0CompletedBasic ScienceBMI >30 kg/m2 / Infertility, Female1
0CompletedBasic ScienceBreast Cancer Survivors1
0CompletedBasic ScienceCoronary Artery Disease1
0CompletedBasic ScienceSleeplessness1
0CompletedTreatmentHealthy Volunteers1
0CompletedTreatmentOverheating / Tiredness1
0CompletedTreatmentPeripheral Vascular Disease (PVD)1
0Enrolling by InvitationBasic ScienceDietary Modifications / Nutrition1
0RecruitingBasic ScienceCancer of the Ovary1
0RecruitingBasic ScienceInflammatory Reaction / Inflammatory Responses / Sleep / Sleep Restriction1
0RecruitingHealth Services ResearchClinical High Risk for Psychosis1
0RecruitingSupportive CareCancers / Tumors, Solid1
0RecruitingTreatmentAntiphospholipid Syndrome in Pregnancy / Pregnancy Loss1
0RecruitingTreatmentStroke, Ischemic1
0Unknown StatusNot AvailableCoronary Angiography1
0Unknown StatusTreatmentAngiogenesis / Cancer, Breast1
1Active Not RecruitingNot AvailableSystemic Lupus Erythematosus (SLE)1
1Active Not RecruitingBasic ScienceHealthy Volunteers1
1Active Not RecruitingTreatmentHealthy Volunteers1
1CompletedNot AvailableHealthy Volunteers2
1CompletedNot AvailableHealthy Volunteers / Pharmacodynamic Interaction1
1CompletedNot AvailableHealthy Volunteers / Pharmacodynamic and Pharmacokinetic Interaction1
1CompletedNot AvailablePeptic Ulcer Disease1
1CompletedNot AvailablePlatelet Inhibition1
1CompletedNot AvailableThrombosis1
1CompletedNot AvailableUlcers / Upper GI Symptoms1
1CompletedBasic ScienceAcute Ischemic Stroke (AIS)1
1CompletedBasic ScienceCardiovascular Disease (CVD)2
1CompletedBasic ScienceDrug Interactions1
1CompletedBasic ScienceHealthy Volunteers3
1CompletedBasic ScienceInhibition on Platelet Aggregation1
1CompletedBasic ScienceThe Focus of the Study is to Monitor MRI Signal Changes and Inflammatory Biomarkers With Use of Aspirin in Patients With Unruptured Cerebral Aneurysm1
1CompletedBasic ScienceThrombosis1
1CompletedOtherInflammatory Reaction1
1CompletedOtherModerate Pain1
1CompletedPreventionCardiovascular Disease (CVD)1
1CompletedPreventionHealthy Volunteers1
1CompletedScreeningAcute Coronary Syndromes (ACS)2
1CompletedTreatmentAcute Coronary Syndromes (ACS)2
1CompletedTreatmentAcute Coronary Syndromes (ACS) / Nonvalvular Atrial Fibrillation1
1CompletedTreatmentAdverse Effect of Antithrombotic Drugs1
1CompletedTreatmentAntiplatelet Effect1
1CompletedTreatmentAspirin Resistance / Pharmacological Aspirin Non-responsiveness1
1CompletedTreatmentAtherosclerosis1
1CompletedTreatmentCoronary Artery Disease2
1CompletedTreatmentHealthy Volunteers14
1CompletedTreatmentHematology / Pain1
1CompletedTreatmentHigh Blood Pressure (Hypertension)1
1CompletedTreatmentHypercholesterolemia, Familial / Mixed hypercholesterolemia1
1CompletedTreatmentHypertriglyceridemias1
1CompletedTreatmentMultiple Myeloma and Plasma Cell Neoplasm1
1CompletedTreatmentPain1
1CompletedTreatmentPain / Pharmacology, Clinical1
1CompletedTreatmentPharmacokinetics2
1CompletedTreatmentPlasma Cell Myeloma1
1CompletedTreatmentPrecancerous Conditions1
1CompletedTreatmentSickle Cell Disorders1
1CompletedTreatmentThrombosis1
1CompletedTreatmentUlcers, Duodenal and Gastric2
1Not Yet RecruitingTreatmentCerebral Infarctions1
1RecruitingOtherJapanese Healthy Adult Male1
1RecruitingTreatmentCoronary Artery Disease1
1RecruitingTreatmentHead and Neck Carcinoma1
1TerminatedNot AvailablePeptic Ulcer Disease1
1Unknown StatusTreatmentChronic Kidney Disease (CKD)1
1Unknown StatusTreatmentStrokes1
1WithdrawnPreventionHealthy Volunteers1
1WithdrawnTreatmentAcute Ischemic Stroke (AIS)1
1WithdrawnTreatmentStroke, Ischemic1
1, 2CompletedPreventionCardiovascular Disease Risk in HIV Patients / Endothelial Function1
1, 2CompletedPreventionUpper Gastrointestinal Mucosal Damage1
1, 2CompletedTreatmentIncreased Drug Resistance1
1, 2CompletedTreatmentMultiple Myeloma (MM)2
2Active Not RecruitingOtherAlpha-1 Antitrypsin Deficiency / Chronic Obstructive Pulmonary Disease (COPD) / Emphysema1
2Active Not RecruitingPreventionAdenomatous Polyps1
2Active Not RecruitingPreventionBarrett Esophagus-Negative for Dysplasia / Dysplasia in Barrett Esophagus / Esophagus, Barrett1
2Active Not RecruitingPreventionColorectal Cancers1
2Active Not RecruitingPreventionCurrent Smokers / Former Smoker / Multiple Pulmonary Nodules / Pulmonary Nodules / Solitary Pulmonary Nodules / Tobacco Use Disorders1
2Active Not RecruitingTreatmentRecurrent Prostate Carcinoma / Stage I Prostate Cancer / Stage IIA Prostate Cancer / Stage IIB Prostate Cancer / Stage III Prostate Cancer1
2Active Not RecruitingTreatmentSepsis1
2CompletedBasic ScienceSkeletal Muscle Mass Regulation1
2CompletedDiagnosticDiabetes Mellitus (DM) / Healthy Volunteers / Platelet Function1
2CompletedDiagnosticDiabetes Mellitus (DM) / Retinopathy, Diabetic1
2CompletedPreventionAcute Respiratory Distress Syndrome (ARDS)1
2CompletedPreventionAneurysm, Coronary / Cardiovascular Disease (CVD) / Heart Diseases / Mucocutaneous Lymph Node Syndrome1
2CompletedPreventionCardiovascular Disease (CVD) / Carotid Stenosis / Cerebral Arteriosclerosis / Cerebrovascular Disorders / Heart Diseases / Vascular Diseases1
2CompletedPreventionCardiovascular Disease (CVD) / Carotid Stenosis / Cerebrovascular Disorders / Heart Diseases / Vascular Diseases1
2CompletedPreventionCardiovascular Disease (CVD) / Human Immunodeficiency Virus (HIV) / Inflammatory Reaction1
2CompletedPreventionEsophageal Cancers / Esophagus, Barrett1
2CompletedPreventionHIV-infected Patients1
2CompletedPreventionIntrauterine Growth Retardation / Preeclampsia / Premature Births / Small for Gestational Age / Very Low Birth Weight Infant1
2CompletedPreventionLung, Carcinoma / Tobacco Use Disorders1
2CompletedPreventionPersistent or Permanent Non-valvular Atrial Fibrillation1
2CompletedPreventionVenous Thromboembolism (VTE)1
2CompletedTreatmentAcute Coronary Syndromes (ACS)2
2CompletedTreatmentAcute Ischemic Stroke (AIS)1
2CompletedTreatmentAtherosclerosis / Myocardial Infarction / Myocardial Ischemia1
2CompletedTreatmentBipolar Disorder (BD)1
2CompletedTreatmentBleeding Complication1
2CompletedTreatmentChronic Obstructive Pulmonary Disease (COPD) / Coronary Artery Disease1
2CompletedTreatmentCoronary Artery Disease1
2CompletedTreatmentGastroduodenal Ulcerations1
2CompletedTreatmentGingival Inflammation / Inflammatory Reaction / Periodontitis1
2CompletedTreatmentHead and Neck Carcinoma / Thromboembolism1
2CompletedTreatmentHealthy Volunteers1
2CompletedTreatmentHigh Risk Essential Thrombocythemia / High Risk Polycythemia Vera1
2CompletedTreatmentInfection, Human Immunodeficiency Virus I3
2CompletedTreatmentIntrauterine Growth Restriction1
2CompletedTreatmentIntrauterine Growth Restriction Asymmetrical1
2CompletedTreatmentLupus / Systemic Lupus Erythematosus (SLE)1
2CompletedTreatmentMetastatic Anaplastic Thyroid Cancer / Metastatic Differentiated Thyroid Cancer / Metastatic Medullary Thyroid Cancer / Metastatic Poorly Differentiated Thyroid Cancer1
2CompletedTreatmentMultiple Myeloma (MM)1
2CompletedTreatmentNeoplasms, Breast1
2CompletedTreatmentPeripheral Arterial Disease (PAD)1
2CompletedTreatmentPlacental Insufficiency1
2CompletedTreatmentPostoperative Dysfunction Following Cardiac Surgery1
2CompletedTreatmentPostoperative; Dysfunction Following Cardiac Surgery1
2CompletedTreatmentPulmonary Hypertension (PH)1
2CompletedTreatmentStable Angina (SA)1
2CompletedTreatmentStable Coronary Artery Disease1
2CompletedTreatmentStroke, Ischemic1
2CompletedTreatmentTuberculous Meningitis1
2Enrolling by InvitationTreatmentAcute Respiratory Distress Syndrome (ARDS)1
2Not Yet RecruitingPreventionHigh Risk Pregnancies1
2Not Yet RecruitingTreatmentAcoustic Schwannoma / Neurofibromatosis 2 / Vestibular Schwannomas1
2Not Yet RecruitingTreatmentAdvanced Non-Small Cell Lung Cancer / EGFR T790M / Non-Small Cell Lung Cancer Stage IIIB2
2Not Yet RecruitingTreatmentIntrauterine Growth Restriction1
2Not Yet RecruitingTreatmentNasopharyngeal Carcinoma1
2RecruitingBasic ScienceAsthma Bronchial / Electrophilic Fatty Acids1
2RecruitingBasic ScienceCirculating Tumor Cells / Epithelial-Mesenchymal Transition1
2RecruitingPreventionAcute Lung Injury (ALI)1
2RecruitingPreventionColorectal Adenomas1
2RecruitingPreventionColorectal Cancer Liver Metastases / Colorectal Cancers / Hepatic Metastases1
2RecruitingPreventionCurrent Every Day Smoker / Multiple Pulmonary Nodules / Pulmonary Nodules / Tobacco Smoking / Tobacco Use Disorders1
2RecruitingPreventionOvarian Cancer Prevention1
2RecruitingPreventionTertiary Prevention in Colon Cancer1
2RecruitingTreatmentAspirin / Cognitive Decline / Cutaneous lesions / Epilepsies / Tuberous Sclerosis Complex (TSC)1
2RecruitingTreatmentCarotid Artery Stenosis1
2RecruitingTreatmentCervical Cancers / Endometrial Cancers / Uterine Cancers1
2RecruitingTreatmentChemoradiation / Locally Advanced Malignant Neoplasm / Rectal Cancer, Adenocarcinoma1
2RecruitingTreatmentCritical Illness1
2RecruitingTreatmentDepression / Depressive Disorders / Major Depressive Disorder (MDD) / Treatment Resistant Depression (TRD)1
2RecruitingTreatmentIntracerebral Hemorrhage / Nonvalvular Atrial Fibrillation2
2RecruitingTreatmentMinor Ischemic Stroke / Transient Ischaemic Attack (TIA)1
2RecruitingTreatmentNeoplasms, Ovarian1
2RecruitingTreatmentPolycythemia Vera (PV)1
2RecruitingTreatmentStage III Cutaneous Melanoma AJCC v7 / Stage IIIA Cutaneous Melanoma AJCC v7 / Stage IIIB Cutaneous Melanoma AJCC v7 / Stage IIIC Cutaneous Melanoma AJCC v7 / Stage IV Cutaneous Melanoma AJCC v6 and v71
2RecruitingTreatmentVenous Thromboembolism (VTE) / Wounds and Injuries1
2TerminatedPreventionColorectal Cancers1
2TerminatedPreventionElevated LDL Cholesterol2
2TerminatedPreventionHuman Immunodeficiency Virus (HIV) Infections1
2TerminatedTreatmentGlioblastomas1
2TerminatedTreatmentPeripheral Artery Disease (PAD)1
2TerminatedTreatmentPulmonary Hypertension (PH)1
2TerminatedTreatmentThrombosis1
2TerminatedTreatmentVenous Leg Ulcer (VLU)1
2Unknown StatusNot AvailableCoronary Arteriosclerosis1
2Unknown StatusPreventionMalignant Neoplasm of Colon / Precancerous Conditions / Rectal Carcinoma1
2Unknown StatusPreventionNeoplasms, Breast1
2Unknown StatusTreatmentAcute Ischemic Stroke (AIS)1
2Unknown StatusTreatmentChronic Obstructive Pulmonary Disease (COPD)1
2Unknown StatusTreatmentMultiple Myeloma (MM)1
2WithdrawnTreatmentPolycythemia Vera (PV)1
2, 3Active Not RecruitingTreatmentIschemic Attack, Transient / Strokes1
2, 3CompletedPreventionAdenoma benign / Colorectal Cancers / Polyps1
2, 3CompletedPreventionStrokes / Transient Ischaemic Attack (TIA)1
2, 3CompletedTreatmentCoronary Artery Bypass Surgery / Stable Angina (SA) / Stable Coronary Artery Disease With Coronary Artery Bypass Grafting1
2, 3CompletedTreatmentCoronary Heart Disease (CHD)1
2, 3CompletedTreatmentIdiopathic Intracranial Hypertension (IIH)1
2, 3CompletedTreatmentImmunoregulation / Inflammatory Reaction / Strokes / Vinpocetine1
2, 3CompletedTreatmentMyocardial Infarction / Strokes1
2, 3Not Yet RecruitingTreatmentCancer, Breast1
2, 3Not Yet RecruitingTreatmentLung Cancer Non-Small Cell Cancer (NSCLC)1
2, 3Not Yet RecruitingTreatmentMultiple Myeloma in Relapse / Multiple Myeloma Progression / Multiple Myeloma Stage I / Multiple Myeloma Stage II / Multiple Myeloma Stage III / Multiple Myeloma With Failed Remission1
2, 3RecruitingTreatmentAcute Exacerbation of Psychosis / Psychosis / Schizophrenic Disorders1
2, 3RecruitingTreatmentAcute Myocardial Infarction (AMI)1
2, 3RecruitingTreatmentAggressive Periodontitis1
2, 3RecruitingTreatmentAggressive Periodontitis / Residual Disease1
2, 3RecruitingTreatmentChagas Disease1
2, 3RecruitingTreatmentRecurrent Pregnancy Losses1
2, 3TerminatedTreatmentStroke, Ischemic / Transient Ischaemic Attack (TIA)1
2, 3Unknown StatusTreatmentAtherosclerosis / Deep Venous Thrombosis / Pulmonary Embolism (PE) / Venous Thromboembolism (VTE)1
2, 3Unknown StatusTreatmentCerebral Infarctions / Strokes / Transient ischemia attacks1
2, 3Unknown StatusTreatmentCoronary Artery Disease1
2, 3Unknown StatusTreatmentCritical Limb Ischemia (CLI)1
2, 3Unknown StatusTreatmentStroke, Ischemic / Transient Ischaemic Attack (TIA)2
3Active Not RecruitingPreventionCancers / Cardiovascular Disease (CVD) / Fracture Bone1
3Active Not RecruitingPreventionEsophageal Cancers / Precancerous Conditions1
3Active Not RecruitingPreventionPrevention & Control1
3Active Not RecruitingPreventionSecondary Preventions / Strokes1
3Active Not RecruitingTreatmentCoronary Artery Disease1
3CompletedPreventionAcute Ischaemic Stroke / Transient Ischaemic Attack (TIA)1
3CompletedPreventionAngina Pectoris / Cardiovascular Disease (CVD) / Coronary Heart Disease (CHD) / Heart Diseases / Myocardial Ischemia1
3CompletedPreventionAtrial Septal Aneurysm / Migraines / Patent Foramen Ovale (PFO) / Stroke, Ischemic1
3CompletedPreventionCardiovascular Disease (CVD)1
3CompletedPreventionCardiovascular Disease (CVD) / Cerebrovascular Disorders / Coronary Heart Disease (CHD) / Heart Diseases / Myocardial Infarction / Myocardial Ischemia / Vascular Diseases1
3CompletedPreventionCardiovascular Disease (CVD) / Coronary Heart Disease (CHD) / Heart Diseases / Myocardial Infarction / Myocardial Ischemia1
3CompletedPreventionCardiovascular Disease (CVD) / Coronary Heart Disease (CHD) / Heart Diseases / Myocardial Ischemia2
3CompletedPreventionCerebral Infarctions2
3CompletedPreventionCerebrovascular Accidents1
3CompletedPreventionColorectal Cancers1
3CompletedPreventionHeart Diseases / Ischaemic Heart Diseases / Myocardial Infarction / Strokes1
3CompletedPreventionModerate Risk of CVD1
3CompletedPreventionNonvalvular Atrial Fibrillation2
3CompletedPreventionNonvalvular Atrial Fibrillation / Vascular Risk1
3CompletedPreventionPreeclampsia2
3CompletedPreventionPulmonary Embolism (PE) / Thromboembolism / Thrombosis / Thrombosis, Venous / Venous Thromboembolism (VTE)1
3CompletedPreventionPulmonary Embolism (PE) / Venous Thromboembolism (VTE)1
3CompletedPreventionRecurrent Abortion1
3CompletedPreventionRenal Failure1
3CompletedPreventionStrokes / Transient Ischaemic Attack (TIA)1
3CompletedPreventionVenous Thromboembolism (VTE)1
3CompletedSupportive CareHealthy Volunteers1
3CompletedTreatmentAcute Coronary Disease / Angina Unstable1
3CompletedTreatmentAcute Coronary Syndromes (ACS)1
3CompletedTreatmentAcute Ischemic Stroke (AIS)1
3CompletedTreatmentAntioxidant Enzyme System / Type 2 Diabetes Mellitus1
3CompletedTreatmentAspirin-Associated Gastric Ulcers1
3CompletedTreatmentBipolar Disorder Depression1
3CompletedTreatmentBlindness / Retinopathy, Diabetic1
3CompletedTreatmentCarotid Artery Dissection / Cervical Artery Dissection / Strokes / Vertebral Artery Dissection1
3CompletedTreatmentCerebrovascular Accidents / High Blood Pressure (Hypertension)1
3CompletedTreatmentCerebrovascular Diseases / Cerebrovascular Disorders1
3CompletedTreatmentCoronary Artery Bypass Grafting (CABG) Surgery / Coronary Artery Disease1
3CompletedTreatmentCoronary Artery Disease1
3CompletedTreatmentCoronary Artery Disease / Diabetes Mellitus (DM) / Renal Insufficiency,Chronic1
3CompletedTreatmentDrugs, Investigational2
3CompletedTreatmentDyslipidemias2
3CompletedTreatmentGastric Ulcer (GU)2
3CompletedTreatmentHealthy Volunteers1
3CompletedTreatmentHeart Failure, Unspecified1
3CompletedTreatmentHigh Blood Pressure (Hypertension)1
3CompletedTreatmentHigh Risk Essential Thrombocythemia / High Risk Polycythemia Vera1
3CompletedTreatmentInfertilities2
3CompletedTreatmentLow Back Pain (LBP)1
3CompletedTreatmentMigraine Disorders2
3CompletedTreatmentMigraine, Acute1
3CompletedTreatmentMucocutaneous Lymph Node Syndrome1
3CompletedTreatmentNeurological Impairments / Stroke, Acute1
3CompletedTreatmentNewly Diagnosed Multiple Myeloma1
3CompletedTreatmentNonvalvular Atrial Fibrillation / Percutaneous Coronary Intervention2
3CompletedTreatmentOsteoarthritis (OA) / Peptic Ulcers1
3CompletedTreatmentAcute Rhinitis / Pharyngitis / Tonsillitis1
3CompletedTreatmentAcute Rhinitis / Pharyngitis1
3CompletedTreatmentPlatelet Function Test1
3CompletedTreatmentProstate Cancer1
3CompletedTreatmentStroke, Ischemic1
3CompletedTreatmentVenous Leg Ulcer (VLU)1
3CompletedTreatmentAcute Rhinitis1
3Not Yet RecruitingPreventionHemorrhage / Thrombosis1
3Not Yet RecruitingPreventionLynch Syndrome I (Site-specific Colonic Cancer)1
3Not Yet RecruitingPreventionRheumatic Heart Disease1
3Not Yet RecruitingTreatmentAbortion in First Trimester1
3Not Yet RecruitingTreatmentDiabetes Mellitus (DM)1
3Not Yet RecruitingTreatmentEndovascular Procedures / Peripheral Arterial Disease (PAD)1
3Not Yet RecruitingTreatmentEsophageal Cancers1
3Not Yet RecruitingTreatmentIntracranial Atherosclerosis1
3Not Yet RecruitingTreatmentNonvalvular Atrial Fibrillation1
3Not Yet RecruitingTreatmentUncontrolled Asthma1
3RecruitingBasic ScienceHypertrophic Obstructive Cardiomyopathy1
3RecruitingDiagnosticAortic Valve Stenosis / Cardiovascular Disease (CVD) / Heart Valve Diseases / Thrombosis / Ventricular Outflow Obstruction1
3RecruitingOtherCancer, Breast / Cancers / Colorectal Cancers / Gastro-oesophageal Cancer / Prostate Cancer1
3RecruitingPreventionAtrial High Rate Episodes1
3RecruitingPreventionBlood Clots / Traumas1
3RecruitingPreventionNoncardioembolic Cerebral Infarction1
3RecruitingPreventionNonvalvular Atrial Fibrillation1
3RecruitingPreventionPeripheral Arterial Disease (PAD)1
3RecruitingPreventionPreeclampsia1
3RecruitingPreventionStrokes1
3RecruitingPreventionThrombosis1
3RecruitingPreventionTranscatheter Aortic Valve Replacement1
3RecruitingPreventionUnruptured Intracranial Aneurysms1
3RecruitingTreatmentAcute Coronary Syndromes (ACS) / Coronary Artery Disease / Stable Angina (SA)1
3RecruitingTreatmentAdjuvant Therapy / Malignant Neoplasm of Colon1
3RecruitingTreatmentCarotid Artery Occlusion / Middle Cerebral Artery Occlusion / Strokes1
3RecruitingTreatmentCentral Retinal Artery Occlusion1
3RecruitingTreatmentCerebral Aneurysms1
3RecruitingTreatmentColorectal Cancers2
3RecruitingTreatmentEmbolic Stroke1
3RecruitingTreatmentMalignant Neoplasm of Colon2
3RecruitingTreatmentNode Positive HER2 Negative Breast Cancer1
3RecruitingTreatmentOsteonecrosis of Femoral Head / Osteonecrosis; Aseptic, Idiopathic1
3RecruitingTreatmentPeripheral Arterial Disease (PAD)1
3RecruitingTreatmentPeripheral Artery Disease (PAD) / Type 2 Diabetes Mellitus1
3RecruitingTreatmentStroke, Acute1
3RecruitingTreatmentType 2 Diabetic Patients1
3SuspendedPreventionProphylaxis of preeclampsia1
3TerminatedPreventionAtherosclerosis / Cerebral Infarctions / Constriction, Pathologic / Strokes1
3TerminatedPreventionCataracts1
3TerminatedPreventionStrokes1
3TerminatedTreatmentAcute Coronary Syndromes (ACS) / Coronary Artery Disease / Myocardial Infarction / Percutaneous Coronary Intervention1
3TerminatedTreatmentColon Adenomas1
3TerminatedTreatmentDisseminated Sclerosis / Tiredness1
3TerminatedTreatmentFibrinolysis / Hemodilution / Retinal Artery Occlusions / Strokes / Visual Acuity1
3TerminatedTreatmentHeadaches1
3TerminatedTreatmentIschemia, Brain / Strokes1
3TerminatedTreatmentMyocardial Infarction / Thrombocytopenias1
3TerminatedTreatmentRetinal Vein Occlusions(RVO)1
3TerminatedTreatmentStrokes1
3Unknown StatusBasic ScienceCardiovascular Disease (CVD) / Polyvascular Disease1
3Unknown StatusPreventionAcute ST Segment Elevation Myocardial Infarction1
3Unknown StatusPreventionCataracts / Macular Degeneration1
3Unknown StatusPreventionColorectal Cancers1
3Unknown StatusPreventionMacular Degeneration1
3Unknown StatusPreventionPreeclampsia1
3Unknown StatusPreventionSquamous Cell Carcinoma (SCC)1
3Unknown StatusPreventionStage 3 Chronic Kidney Disease / Stage 4 Chronic Kidney Disease1
3Unknown StatusTreatmentAspirin / Coronary Artery Disease / Off-pump Coronary Artery Bypass1
3Unknown StatusTreatmentAtherosclerosis1
3Unknown StatusTreatmentCoronary Artery Bypass Grafting (CABG) Surgery / Graft Patency / Hypercoagulability / Thrombosis1
3Unknown StatusTreatmentCoronary Artery Disease4
3Unknown StatusTreatmentCoronary Artery Stenosis / High Post-Treatment Platelet Reactivity / Late Platelet Aggregation / Maximal Platelet Aggregation1
3Unknown StatusTreatmentHepatocellular,Carcinoma / Recurrences1
3Unknown StatusTreatmentSchizoaffective Disorders / Schizophrenic Disorders1
3Unknown StatusTreatmentTo Investigate the Effects of Low Dose Aspirin and Low Molecular Weight Heparin in IVF Out Come1
3WithdrawnTreatmentAspirin / Lung Cancer Non-Small Cell Cancer (NSCLC) / Survival1
4Active Not RecruitingOtherAcute Coronary Syndromes (ACS)1
4Active Not RecruitingPreventionAortic Valve Disorder / Haemorrhage / Major Bleeding / Myocardial Infarction / Strokes1
4Active Not RecruitingPreventionAspirin / Coronary Artery Disease1
4Active Not RecruitingPreventionCancers / Dementias / Depression / Functional Disability / Haemorrhage / Heart Diseases / Strokes1
4Active Not RecruitingPreventionDiabetes Mellitus (DM)1
4Active Not RecruitingPreventionIntracranial Hemorrhages / Ischemia, Brain1
4Active Not RecruitingSupportive CareCardiovascular Disease (CVD) / Interventional Cardiology1
4Active Not RecruitingTreatmentAntiplatelet Agents / Coronary Artery Bypass Graft1
4Active Not RecruitingTreatmentCerebral Small Vessels Disease1
4Active Not RecruitingTreatmentCoronary Artery Disease1
4Active Not RecruitingTreatmentCoronary Microvascular Perfusion in Patients With Ischemic Heart Disease1
4Active Not RecruitingTreatmentHeart Failure, Unspecified1
4Active Not RecruitingTreatmentIntracranial Hemorrhages / Ischemia, Brain1
4Active Not RecruitingTreatmentPercutaneous Coronary Intervention1
4CompletedNot AvailableCoronary Artery Disease1
4CompletedNot AvailableGastroduodenal Ulcers1
4CompletedBasic ScienceAcute Coronary Syndromes (ACS) / Nonvalvular Atrial Fibrillation1
4CompletedBasic ScienceAcute Coronary Syndromes (ACS) / Novel P2Y12 Inhibitors / Platelet Function and Reactivity Tests1
4CompletedBasic ScienceAtherosclerosis1
4CompletedBasic ScienceAtherothrombosis1
4CompletedBasic ScienceDRUG REACTIONS1
4CompletedBasic ScienceType 2 Diabetes Mellitus1
4CompletedDiagnosticAcute Coronary Syndromes (ACS) / Atherosclerosis / Cardiovascular Disease (CVD) / Cerebral Infarctions / Strokes / Thrombosis / Transient ischemia attacks / Vascular Diseases1
4CompletedDiagnosticCoronary Artery Disease / Type 2 Diabetes Mellitus1
4CompletedDiagnosticIntermittent Claudication1
4CompletedHealth Services ResearchAtherothrombosis1
4CompletedHealth Services ResearchPeripheral Arterial Disease (PAD)1
4CompletedPreventionAcute Coronary Syndromes (ACS)1
4CompletedPreventionAdverse Effects / Coronary Artery Atherosclerosis / Insulin resistance syndrome1
4CompletedPreventionAortic Valve Disorder / Myocardial Infarction / Strokes1
4CompletedPreventionArteriosclerosis / Coronary Heart Disease (CHD) / Type 2 Diabetes Mellitus1
4CompletedPreventionArteriosclerosis / Ischemia, Brain / Transient Ischaemic Attack (TIA)1
4CompletedPreventionAtherosclerosis / Cardiovascular Disease (CVD) / Metabolic Syndromes1
4CompletedPreventionAtherosclerosis / Systemic Lupus Erythematosus (SLE) / Thromboembolism1
4CompletedPreventionC.Medical Procedure; Vascular, Functional or Late / Cardiovascular Risk Factors / Hemostatic Balance1
4CompletedPreventionCardiovascular Disease (CVD)1
4CompletedPreventionCerebral Infarctions1
4CompletedPreventionCerebral Infarctions / Strokes1
4CompletedPreventionCoronary Artery Disease / Platelet Aggregation / Platelet Transcriptome1
4CompletedPreventionHealthy Volunteers1
4CompletedPreventionHeart Diseases1
4CompletedPreventionIntra-uterine Growth Restriction / Prophylaxis of preeclampsia1
4CompletedPreventionIntrauterine Growth Retardation / Placental Insufficiency / Premature Births / Prophylaxis of preeclampsia1
4CompletedPreventionOvarian Hyperstimulation Syndrome1
4CompletedPreventionPatent Foramen Ovale (PFO) / Stroke, Ischemic1
4CompletedPreventionPeptic Ulcers1
4CompletedPreventionStrokes1
4CompletedPreventionThrombosis1
4CompletedSupportive CareDyslipidemias / Facial Flushing / Hyperlipidemias1
4CompletedSupportive CareUnderweight1
4CompletedTreatmentAcute Coronary Syndromes (ACS)1
4CompletedTreatmentAcute Coronary Syndromes (ACS) / Clopidogrel Low Responsiveness / Percutaneous Coronary Intervention1
4CompletedTreatmentAcute Coronary Syndromes (ACS) / Coronary Artery Disease1
4CompletedTreatmentAcute Ischemic Stroke (AIS)2
4CompletedTreatmentAnalgesics1
4CompletedTreatmentAngina Pectoris / Atherosclerosis / Coronary Heart Disease (CHD)1
4CompletedTreatmentAntiplatelet Therapy of Coronary Artery Bypass1
4CompletedTreatmentArthritis / Myocardial Infarction1
4CompletedTreatmentAsthma, Aspirin-Induced1
4CompletedTreatmentAtherosclerosis / Cardiovascular Disease (CVD) / Myocardial Infarction1
4CompletedTreatmentBMI >30 kg/m2 / Hypertension,Essential1
4CompletedTreatmentCVD1
4CompletedTreatmentCardiovascular Disease (CVD) / High Blood Pressure (Hypertension)1
4CompletedTreatmentCerebral Infarctions2
4CompletedTreatmentChronic Total Occlusion of Coronary Artery / Coronary Artery Disease / Coronary Artery Restenosis / Coronary Artery Stenosis / Coronary Heart Disease (CHD) / Myocardial Ischemia / Vascular Diseases1
4CompletedTreatmentCoronary Arteriosclerosis2
4CompletedTreatmentCoronary Artery Disease13
4CompletedTreatmentCoronary Artery Disease / Myocardial Ischemia / Stent Thrombosis1
4CompletedTreatmentCoronary Artery Disease / Type 2 Diabetes Mellitus1
4CompletedTreatmentCoronary Heart Disease (CHD)2
4CompletedTreatmentCoronary Heart Disease (CHD) / Platelet Aggregation Inhibitors1
4CompletedTreatmentDementia, Vascular / Strokes1
4CompletedTreatmentDiabetes Mellitus (DM)2
4CompletedTreatmentDiabetes, Diabetes Mellitus Type 11
4CompletedTreatmentDrug Action Increased1
4CompletedTreatmentEsophagus, Barrett1
4CompletedTreatmentFevers / Respiratory Tract Infections (RTI)1
4CompletedTreatmentHaemorrhage / Thromboembolism1
4CompletedTreatmentHeadache, Tension-Type / Headaches / Tension-Type Headache (Episodic)1
4CompletedTreatmentHealthy Volunteers2
4CompletedTreatmentHeart Failure, Unspecified1
4CompletedTreatmentHemorrhage / Systemic Embolism / Thrombosis1
4CompletedTreatmentHigh Blood Pressure (Hypertension) / Liver Cirrhosis / Status;Splenectomy / Thrombosis, Venous1
4CompletedTreatmentIndigestion1
4CompletedTreatmentInfluence of Aspirin on the Pharmacokinetics/Pharmacodynamics of Clopidogrel / Influence of Genotype of Drug Metabolizing Enzyme or Transporter on the Pharmacokinetics/Pharmacodynamics of Clopidogrel1
4CompletedTreatmentIschaemic Heart Diseases1
4CompletedTreatmentMyocardial Infarction1
4CompletedTreatmentNonvalvular Atrial Fibrillation1
4CompletedTreatmentPain, Migraine1
4CompletedTreatmentPeptic Ulcers1
4CompletedTreatmentPeripheral Arterial Disease (PAD)1
4CompletedTreatmentAcute Rhinitis / Pharyngitis / Tonsillitis1
4CompletedTreatmentPrimary Total Hip and Knee Arthroplasty1
4CompletedTreatmentRelapsing Remitting Multiple Sclerosis (RRMS)1
4CompletedTreatmentStrokes1
4CompletedTreatmentVasospastic Syndrome1
4CompletedTreatmentAcute Rhinitis1
4Enrolling by InvitationPreventionCancers1
4Enrolling by InvitationTreatmentChronic Total Occlusion of Coronary Artery / Coronary Artery Disease / Percutaneous Coronary Intervention / Viable Myocardium1
4Enrolling by InvitationTreatmentComplete Occlusion of Coronary Artery / Hibernation, Myocardial1
4Enrolling by InvitationTreatmentHematuria / Urinary Bladder Neoplasms1
4Enrolling by InvitationTreatmentSclerosis, Progressive Systemic1
4Not Yet RecruitingBasic ScienceArtery Occlusion / Aspirin Sensitivity / Cardiovascular Disease (CVD) / Clopidogrel, Poor Metabolism of / Coronary Artery Disease / Coronary Heart Disease (CHD) / Heart Diseases / Myocardial Ischemia / Platelet Thrombus / Platelets Dysfunction1
4Not Yet RecruitingDiagnosticComplications1
4Not Yet RecruitingHealth Services ResearchCoronary Artery Disease1
4Not Yet RecruitingPreventionType 2 Diabetes Mellitus1
4Not Yet RecruitingTreatmentAnginal Pain1
4Not Yet RecruitingTreatmentCoronary Artery Disease / Percutaneous Coronary Intervention1
4Not Yet RecruitingTreatmentEmbolic Stroke1
4Not Yet RecruitingTreatmentLeft Atrial Appendage Closure / Non-valvular Atrial Fibrillation (NVAF)1
4Not Yet RecruitingTreatmentLeukemias1
4RecruitingDiagnosticCardiovascular Disease (CVD)1
4RecruitingDiagnosticCoronary Artery Disease1
4RecruitingHealth Services ResearchCoronary Artery Disease / Myocardial Infarction / Peripheral Vascular Disease (PVD)1
4RecruitingPreventionAortic Valve Disorder / Haemorrhage / Myocardial Infarction / Strokes1
4RecruitingPreventionAortic Valve Insufficiency / Aortic Valve Stenosis / Thrombosis1
4RecruitingPreventionAspirin / GnRH Antagonist / Ovarian Hyperstimulation Syndrome / Pigment Epithelium Derived Factor / Vascular Endothelial Growth Factor1
4RecruitingPreventionHigh Blood Pressure (Hypertension) / Liver Cirrhosis / Status;Splenectomy / Thrombosis, Venous1
4RecruitingPreventionNonvalvular Atrial Fibrillation1
4RecruitingPreventionNonvalvular Atrial Fibrillation / Strokes2
4RecruitingPreventionProstate Cancer1
4RecruitingPreventionSaphenous Vein Graft Disease1
4RecruitingPreventionThromboprophylaxis / Traumas / Venous Thromboembolism (VTE)1
4RecruitingPreventionType 2 Diabetes Mellitus1
4RecruitingSupportive CarePulmonary Embolism (PE) / Thrombosis, Venous1
4RecruitingTreatmentAntiplatelet Therapy / Percutaneous Coronary Intervention / Stable Coronary Syndrome / Ticagrelor1
4RecruitingTreatmentAortic Valve Stenosis / Strokes1
4RecruitingTreatmentAtherosclerosis / Coronary Artery Disease / Stents1
4RecruitingTreatmentCarotid Atherosclerosis / Type 2 Diabetes Mellitus1
4RecruitingTreatmentCervical Artery Dissection1
4RecruitingTreatmentChagas Disease With Heart Failure1
4RecruitingTreatmentCoronary Artery Disease1
4RecruitingTreatmentCoronary Artery Disease / Nonvalvular Atrial Fibrillation1
4RecruitingTreatmentCoronary Artery Disease / Type 2 Diabetes Mellitus1
4RecruitingTreatmentCoronary Heart Disease (CHD)1
4RecruitingTreatmentCoronary Heart Disease (CHD) / Percutaneous Transluminal Coronary Angioplasty1
4RecruitingTreatmentDiabetes Mellitus (DM) / Myocardial Infarction / Peripheral Arterial Disease (PAD)1
4RecruitingTreatmentGastrointestinal Injury / Ischaemic Heart Diseases1
4RecruitingTreatmentHigh Blood Pressure (Hypertension)1
4RecruitingTreatmentIschemic Cerebrovascular Accident1
4RecruitingTreatmentMyocardial Infarction1
4RecruitingTreatmentNonvalvular Atrial Fibrillation1
4RecruitingTreatmentNonvalvular Atrial Fibrillation / Valve Heart Disease1
4RecruitingTreatmentPeripheral Arterial Disease (PAD)1
4RecruitingTreatmentProlonged DAPT in ACS Patients With Hisk of Both Ischemic and Hemorrhage1
4RecruitingTreatmentRecurrent Pregnancy Losses1
4RecruitingTreatmentThrombophilia With Recurrent Pregnancy Loss1
4RecruitingTreatmentTranscatheter Aortic Valve Replacement1
4TerminatedBasic SciencePlatelet Aggregation1
4TerminatedDiagnosticAcute Coronary Syndromes (ACS) / Thrombosis1
4TerminatedPreventionAtherosclerosis / Carotid Artery Stenosis / Strokes1
4TerminatedPreventionMyocardial Injury1
4TerminatedPreventionType 2 Diabetes Mellitus1
4TerminatedPreventionVentricular Tachycardia (VT)1
4TerminatedTreatmentCoronary Graft Patency1
4TerminatedTreatmentFontan Procedure1
4TerminatedTreatmentHigh-Normal Blood Pressure / Mild Essential Hypertension1
4TerminatedTreatmentPericarditis1
4TerminatedTreatmentPeripheral Arterial Disease (PAD)1
4Unknown StatusBasic SciencePeripheral Arterial Disease (PAD)1
4Unknown StatusPreventionComplications Due to Heart Valve Prosthesis1
4Unknown StatusPreventionDiabetes Mellitus (DM) / High Blood Pressure (Hypertension) / Hyperlipidemias1
4Unknown StatusPreventionDiabetic Nephropathies1
4Unknown StatusPreventionHemorrhage, Gastrointestinal1
4Unknown StatusPreventionStrokes / Transient Ischaemic Attack (TIA)1
4Unknown StatusPreventionThrombosis1
4Unknown StatusPreventionType 2 Diabetes Mellitus1
4Unknown StatusTreatmentAbortions spontaneous / Pregnancy1
4Unknown StatusTreatmentAcute Coronary Syndromes (ACS)1
4Unknown StatusTreatmentCoronary Artery Disease3
4Unknown StatusTreatmentCoronary Artery Disease / Nonvalvular Atrial Fibrillation1
4Unknown StatusTreatmentDiabetes Mellitus (DM) / Microalbuminuria1
4Unknown StatusTreatmentEnd-Stage Renal Disease (ESRD)1
4Unknown StatusTreatmentType 2 Diabetes Mellitus1
4WithdrawnPreventionChronic Kidney Disease (CKD) / Nonvalvular Atrial Fibrillation1
4WithdrawnPreventionDeep Vein Thrombosis (DVT) / PE - Pulmonary Thromboembolism1
4WithdrawnTreatmentCoronary Artery Disease1
Not AvailableActive Not RecruitingBasic ScienceHuman Immunodeficiency Virus (HIV)1
Not AvailableActive Not RecruitingPreventionIschemia, Brain / Strokes1
Not AvailableActive Not RecruitingTreatmentCancer Patients First-ever Acute Ischemic Stroke1
Not AvailableCompletedNot AvailableAspirin Blood Level / Proton Pump Inhiditor Treatment1
Not AvailableCompletedNot AvailableAspirin Hypersensitivity1
Not AvailableCompletedNot AvailableAspirin / Drug Safety / Longterm Effects1
Not AvailableCompletedNot AvailableAtherosclerosis / Cardiovascular Disease (CVD) / Carotid Stenosis / Strokes1
Not AvailableCompletedNot AvailableCoronary Heart Disease (CHD) / Ischaemic Heart Diseases / Secondary Preventions / Strokes1
Not AvailableCompletedNot AvailableFacial Flushing1
Not AvailableCompletedNot AvailableHealthy Volunteers2
Not AvailableCompletedNot AvailableMammographic Breast Density1
Not AvailableCompletedNot AvailableRenal haematoma / Urolithiasis1
Not AvailableCompletedNot AvailableUnsuspected Pulmonary Embolism1
Not AvailableCompletedBasic ScienceBlood Platelets / Clopidogrel1
Not AvailableCompletedBasic ScienceEndotoxaemia2
Not AvailableCompletedBasic ScienceHealthy Volunteers2
Not AvailableCompletedBasic ScienceHeart Diseases / Vascular Diseases1
Not AvailableCompletedBasic SciencePhysiology of Microvascular Skin1
Not AvailableCompletedBasic SciencePlatelet Dysfunction Due to Aspirin1
Not AvailableCompletedBasic ScienceType 2 Diabetes Mellitus2
Not AvailableCompletedDiagnosticCoronary Artery Disease1
Not AvailableCompletedDiagnosticDrug Resistance2
Not AvailableCompletedPreventionAtherosclerosis / Cardiovascular Disease (CVD) / Cerebral Arteriosclerosis / Coronary Heart Disease (CHD) / Diabetes Mellitus (DM) / Heart Diseases / High Blood Pressure (Hypertension)1
Not AvailableCompletedPreventionCardiovascular Disease (CVD)2
Not AvailableCompletedPreventionCardiovascular Disease (CVD) / Coronary Heart Disease (CHD) / Heart Diseases1
Not AvailableCompletedPreventionHeat Stress Disorders1
Not AvailableCompletedPreventionImpaired Glucose Tolerance (IGT) / Prediabetic State1
Not AvailableCompletedPreventionOsteoarthritis (OA)1
Not AvailableCompletedPreventionProstate Cancer1
Not AvailableCompletedPreventionHemodialysis-dependent patients1
Not AvailableCompletedSupportive CareBone Metastases / Musculoskeletal Cancer / Soft Tissue Sarcoma (STS) / Thromboembolism1
Not AvailableCompletedSupportive CareExtrauterine Pregnancy / Intrauterine Fetal Growth Restriction / Miscarriage Less Than 12 Gestational Weeks / Preeclampsia / Pregnancy1
Not AvailableCompletedSupportive CareFacial Flushing / High Blood Cholesterol Level1
Not AvailableCompletedTreatmentAcute Myocardial Infarction (AMI)1
Not AvailableCompletedTreatmentAngioplasty / Atherosclerosis1
Not AvailableCompletedTreatmentAspirin Resistance / High Blood Cholesterol Level1
Not AvailableCompletedTreatmentBirth / Spontaneous Abortions1
Not AvailableCompletedTreatmentCardiovascular Disease (CVD) / Cerebrovascular Diseases / Peripheral Arterial Disease (PAD)1
Not AvailableCompletedTreatmentCardiovascular Disease (CVD) / Cerebrovascular Disorders1
Not AvailableCompletedTreatmentCarotid Artery Stenosis1
Not AvailableCompletedTreatmentClopidogrel Non-Responsiveness1
Not AvailableCompletedTreatmentCoronary Artery Disease3
Not AvailableCompletedTreatmentCoronary Heart Disease (CHD)1
Not AvailableCompletedTreatmentDesmopressin / Hemodilution / Mild Hypothermia / NSAIDs / Platelets Dysfunction1
Not AvailableCompletedTreatmentIntrauterine Adhesions1
Not AvailableCompletedTreatmentIschaemic Heart Diseases1
Not AvailableCompletedTreatmentKnee Osteoarthritis (Knee OA)1
Not AvailableCompletedTreatmentMyeloproliferative Disorders / Thrombocythemia1
Not AvailableCompletedTreatmentMyocardial Infarction1
Not AvailableCompletedTreatmentMyocardial Ischemia1
Not AvailableCompletedTreatmentPreeclampsia1
Not AvailableCompletedTreatmentRecurrent Abortion1
Not AvailableEnrolling by InvitationPreventionAtherosclerotic Cardiovascular Diseases1
Not AvailableEnrolling by InvitationPreventionColorectal Cancers1
Not AvailableEnrolling by InvitationTreatmentInguinal Hernias / Postoperative Complications / Postoperative Hemorrhages1
Not AvailableEnrolling by InvitationTreatmentMucocutaneous Lymph Node Syndrome1
Not AvailableEnrolling by InvitationTreatmentPeripheral Artery Disease (PAD)1
Not AvailableNo Longer AvailableNot AvailableDiabetes, Diabetes Mellitus Type 11
Not AvailableNot Yet RecruitingNot AvailableRecurrent Implantation Failure (RIF)1
Not AvailableNot Yet RecruitingBasic ScienceCardiovascular Disease (CVD) / Platelet Dysfunction Due to Aspirin1
Not AvailableNot Yet RecruitingDiagnosticAspirin1
Not AvailableNot Yet RecruitingPreventionBrain Infarction1
Not AvailableNot Yet RecruitingPreventionIschemic Attack, Transient / Stroke, Acute1
Not AvailableNot Yet RecruitingPreventionCaudal epidural block therapy / Postoperative pain / Surgery, Cardiac1
Not AvailableNot Yet RecruitingTreatmentForamen Ovale, Patent1
Not AvailableNot Yet RecruitingTreatmentStable Angina (SA)1
Not AvailableNot Yet RecruitingTreatmentStrokes1
Not AvailableRecruitingNot AvailableAsthma, Aspirin-Induced1
Not AvailableRecruitingNot AvailableCoronary Artery Disease1
Not AvailableRecruitingNot AvailableMyocardium; Injury1
Not AvailableRecruitingNot AvailableStroke, Ischemic1
Not AvailableRecruitingNot AvailableStrokes / Transient Ischaemic Attack (TIA)1
Not AvailableRecruitingBasic ScienceAdenocarcinoma of the Lung / Recurrent Non-small Cell Lung Cancer / Stage IA Non-small Cell Lung Cancer / Stage IB Non-small Cell Lung Cancer / Stage IIA Non-small Cell Lung Cancer / Stage IIB Non-small Cell Lung Cancer / Stage IIIA Non-Small Cell Lung Cancer / Stage IIIb Non-small Cell Lung Cancer1
Not AvailableRecruitingPreventionAspirin / Microbiota1
Not AvailableRecruitingPreventionComplication of Cardiac Defibrillator / Disorder of Cardiac Pacemaker System / Venous Occlusion1
Not AvailableRecruitingTreatmentAcute Coronary Syndromes (ACS)1
Not AvailableRecruitingTreatmentAnterior Ischemic Optic Neuropathy1
Not AvailableRecruitingTreatmentAspirin / Platelet Dysfunction Due to Drugs / Ticagrelor / Transfusions1
Not AvailableRecruitingTreatmentBiliary Stasis, Extrahepatic1
Not AvailableRecruitingTreatmentChronic Periodontitis / Diabetes Mellitus (DM)1
Not AvailableRecruitingTreatmentChronic Subdural Hematomas1
Not AvailableRecruitingTreatmentCoronary Artery Disease / High Bleeding Risk / Percutaneous Coronary Intervention1
Not AvailableRecruitingTreatmentHepatocellular,Carcinoma1
Not AvailableRecruitingTreatmentIntrauterine Growth Restriction Asymmetrical1
Not AvailableRecruitingTreatmentPremature Births1
Not AvailableRecruitingTreatmentSystemic Lupus Erythematosus (SLE)1
Not AvailableTerminatedNot AvailableAcute Coronary Syndromes (ACS) / Coronary Artery Disease / Stable Angina (SA)1
Not AvailableTerminatedDiagnosticAortic Valve Disorder1
Not AvailableTerminatedPreventionPreeclampsia1
Not AvailableTerminatedPreventionThoracic Pain1
Not AvailableTerminatedTreatmentAntiphospholipid Antibody Syndrome / Recurrent Pregnancy Losses1
Not AvailableTerminatedTreatmentSoft Tissue Neoplasms1
Not AvailableTerminatedTreatmentStable Angina (SA)1
Not AvailableUnknown StatusNot AvailableBleeding Complication During Colon Polypectomy1
Not AvailableUnknown StatusNot AvailableCancer, Breast1
Not AvailableUnknown StatusBasic ScienceHealthy Volunteers1
Not AvailableUnknown StatusBasic ScienceMalignant Neoplasm of Colon1
Not AvailableUnknown StatusDiagnosticASA Intolerant Asthma / Asthma Aspirin-sensitive / Asthma, Aspirin-Induced / Asthma, Nasal Polyps, And Aspirin Intolerance1
Not AvailableUnknown StatusPreventionColorectal Cancers1
Not AvailableUnknown StatusPreventionHard of Hearing / Ototoxicity1
Not AvailableUnknown StatusTreatmentMild Cognitive Impairment (MCI)1
Not AvailableUnknown StatusTreatmentStroke, Ischemic1
Not AvailableWithdrawnNot AvailableAcute Coronary Syndromes (ACS) / Non ST Elevation Myocardial Infarction / ST Elevation Myocardial Infarction / Unstable Angina (UA)1
Not AvailableWithdrawnBasic SciencePlatelet Aggregation1
Not AvailableWithdrawnPreventionCardiovascular Disease (CVD)1
Not AvailableWithdrawnPreventionCarotid Artery Injury / Vertebral Artery Injury1
Not AvailableWithdrawnScreeningChronic Migraine / Episodic Migraine1

Pharmacoeconomics

Manufacturers
  • Bayer healthcare llc
Packagers
  • A-S Medication Solutions LLC
  • BASF Corp.
  • Excellium Pharmaceutical Inc.
  • Harvest Pharmaceuticals Inc.
  • Kaiser Foundation Hospital
  • Major Pharmaceuticals
  • Mckesson Corp.
  • Par Pharmaceuticals
  • Prepak Systems Inc.
  • Rosedale Therapeutics
  • Time-Cap Labs
  • United Research Laboratories Inc.
Dosage forms
FormRouteStrength
TabletOral500 mg
TabletOral300 mg
Kit; tablet, delayed release; tablet, extended releaseOral
Capsule, extended releaseOral
Capsule; capsule, extended releaseOral
Tablet, effervescentOral
KitOral
Granule, effervescentOral
Tablet, delayed releaseOral600 mg
SuppositoryRectal150 mg
SuppositoryRectal650 mg
Tablet, chewableOral80 mg
Tablet, delayed releaseOral162 mg
Tablet, film coatedOral500 mg/1
Tablet, film coatedOral325 mg/1
Gum, chewingOral325 mg
SuppositoryRectal300 mg/1
SuppositoryRectal600 mg/1
TabletOral325 g/1
Tablet, coatedOral325 ng/1
Tablet, extended releaseOral81 mg/1
Tablet, delayed release; tablet, extended releaseOral325 mg
Tablet, delayed release; tablet, extended releaseOral500 mg
Tablet, delayed releaseOral81 mg/811
GranuleOral500 mg
Tablet, coatedOral500 mg/5001
Tablet, chewableOral81 mg/1
Tablet, coatedOral81 mg/1
TabletOral500 mg/1
Tablet, coatedOral325 mg/1
PowderOral500 mg/1
Tablet, coatedOral500 mg/1
TabletOral81 mg/1
Kit
PowderOral325 mg/1
KitTopical
PasteDental
Tablet, film coatedOral
Capsule, extended releaseOral162.5 mg/1
KitOral; Topical
Tablet, delayed releaseOral325 mg/3251
Tablet, delayed releaseOral325 mg/1
Tablet, delayed releaseOral325 mg
Tablet, delayed releaseOral650 mg
Tablet, chewableOral81 mg
Tablet, delayed releaseOral500 mg
Tablet, delayed releaseOral975 mg
Tablet, delayed releaseOral81 mg
Tablet, chewableOral325 mg
Capsule, gelatin coatedOral
Tablet, coatedOral
Tablet, orally disintegratingOral81 mg/1
Tablet, film coatedOral81 mg/1
Kit
Tablet, delayed releaseOral81 mg/1
Capsule, coatedOral
TabletTopical
PowderOral
Tablet, multilayerOral
TabletOral325 1/1
Kit; tablet; tablet, delayed releaseOral
CapsuleOral
TabletOral325 mg
TabletOral81 mg
Tablet, delayed releaseOral80 mg
TabletOral80 mg
TabletOral
TabletOral325 mg/1
StripOral81 mg/1
TabletOral81 mg/81mg
TabletOral325 mg/325mg
Prices
Unit descriptionCostUnit
Entrophen 10 650 mg Enteric-Coated Tablet0.09USD tablet
DrugBank does not sell nor buy drugs. Pricing information is supplied for informational purposes only.
Patents
Patent NumberPediatric ExtensionApprovedExpires (estimated)
US5972916No1997-07-142017-07-14Us
US6015577No1997-01-182017-01-18Us
US6926907No2003-02-282023-02-28Us
US9101637No2002-03-232022-03-23Us
US9226892No2012-09-292032-09-29Us
US8865187No2002-03-232022-03-23Us
US9216150No2012-09-292032-09-29Us
US9351984No2001-12-192021-12-19Us
US9539214No2013-03-132033-03-13Us
US9364439No2002-05-312022-05-31Us
US8206741No2003-02-282023-02-28Us

Properties

State
Solid
Experimental Properties
PropertyValueSource
melting point (°C)135 °CPhysProp
boiling point (°C)140 °CNot Available
water solubility4600 mg/L (at 25 °C)YALKOWSKY,SH & DANNENFELSER,RM (1992)
logP1.19HANSCH,C ET AL. (1995)
Caco2 permeability-5.06ADME Research, USCD
pKa3.49 (at 25 °C)MERCK INDEX (1983)
Predicted Properties
PropertyValueSource
Water Solubility1.46 mg/mLALOGPS
logP1.43ALOGPS
logP1.24ChemAxon
logS-2.1ALOGPS
pKa (Strongest Acidic)3.41ChemAxon
pKa (Strongest Basic)-7.1ChemAxon
Physiological Charge-1ChemAxon
Hydrogen Acceptor Count3ChemAxon
Hydrogen Donor Count1ChemAxon
Polar Surface Area63.6 Å2ChemAxon
Rotatable Bond Count3ChemAxon
Refractivity44.45 m3·mol-1ChemAxon
Polarizability17.1 Å3ChemAxon
Number of Rings1ChemAxon
Bioavailability1ChemAxon
Rule of FiveYesChemAxon
Ghose FilterYesChemAxon
Veber's RuleNoChemAxon
MDDR-like RuleNoChemAxon
Predicted ADMET features
PropertyValueProbability
Human Intestinal Absorption+0.9645
Blood Brain Barrier+0.9376
Caco-2 permeable-0.6607
P-glycoprotein substrateNon-substrate0.685
P-glycoprotein inhibitor INon-inhibitor0.9118
P-glycoprotein inhibitor IINon-inhibitor0.9615
Renal organic cation transporterNon-inhibitor0.914
CYP450 2C9 substrateNon-substrate0.7518
CYP450 2D6 substrateNon-substrate0.9116
CYP450 3A4 substrateNon-substrate0.7225
CYP450 1A2 substrateNon-inhibitor0.9046
CYP450 2C9 inhibitorNon-inhibitor0.9071
CYP450 2D6 inhibitorNon-inhibitor0.9576
CYP450 2C19 inhibitorNon-inhibitor0.9445
CYP450 3A4 inhibitorNon-inhibitor0.9611
CYP450 inhibitory promiscuityLow CYP Inhibitory Promiscuity0.9557
Ames testNon AMES toxic0.9326
CarcinogenicityNon-carcinogens0.8356
BiodegradationReady biodegradable0.9067
Rat acute toxicity2.6386 LD50, mol/kg Not applicable
hERG inhibition (predictor I)Weak inhibitor0.9433
hERG inhibition (predictor II)Non-inhibitor0.9799
ADMET data is predicted using admetSAR, a free tool for evaluating chemical ADMET properties. (23092397)

Spectra

Mass Spec (NIST)
Download (8.27 KB)
Spectra
SpectrumSpectrum TypeSplash Key
GC-MS Spectrum - GC-EI-TOF (Pegasus III TOF-MS system, Leco; GC 6890, Agilent Technologies)GC-MSsplash10-014l-2960000000-ffcb8d28ab7e460b0da8
GC-MS Spectrum - GC-MS (1 TMS)GC-MSsplash10-006w-2910000000-910e8ce2493a05870b33
Predicted GC-MS Spectrum - GC-MSPredicted GC-MSNot Available
GC-MS Spectrum - EI-BGC-MSsplash10-00dl-9400000000-64327d3bef0063cf4fe1
GC-MS Spectrum - CI-BGC-MSsplash10-00di-0900000000-113943b65024522c1712
GC-MS Spectrum - EI-BGC-MSsplash10-014i-1590000000-7890c99ca2b0e2c4ff19
GC-MS Spectrum - GC-EI-TOFGC-MSsplash10-014l-2960000000-ffcb8d28ab7e460b0da8
GC-MS Spectrum - GC-MSGC-MSsplash10-006w-2910000000-910e8ce2493a05870b33
GC-MS Spectrum - GC-EI-TOFGC-MSsplash10-006w-2900000000-253eb678a85f77d4ba61
Mass Spectrum (Electron Ionization)MSsplash10-00dl-6900000000-74f8a29aa18d0c3afe98
MS/MS Spectrum - Quattro_QQQ 10V, Positive (Annotated)LC-MS/MSsplash10-00kr-6900000000-324f46e8def1652ed4bf
MS/MS Spectrum - Quattro_QQQ 25V, Positive (Annotated)LC-MS/MSsplash10-000i-9000000000-cdf64eaf75083da6f355
MS/MS Spectrum - Quattro_QQQ 40V, Positive (Annotated)LC-MS/MSsplash10-000i-9000000000-ee75806b6fb8a38fd697
MS/MS Spectrum - EI-B (Unknown) , PositiveLC-MS/MSsplash10-00dl-9400000000-64327d3bef0063cf4fe1
MS/MS Spectrum - CI-B (Unknown) , PositiveLC-MS/MSsplash10-00di-0900000000-113943b65024522c1712
Predicted MS/MS Spectrum - 10V, Positive (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 20V, Positive (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 40V, Positive (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 10V, Negative (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 20V, Negative (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 40V, Negative (Annotated)Predicted LC-MS/MSNot Available
LC-MS/MS Spectrum - LC-ESI-QFT , negativeLC-MS/MSsplash10-000i-1900000000-bc50013edb10656e0aa4
LC-MS/MS Spectrum - LC-ESI-QFT , negativeLC-MS/MSsplash10-000i-2900000000-8c55c1f8d7cb7f247a5d
LC-MS/MS Spectrum - LC-ESI-QFT , negativeLC-MS/MSsplash10-000l-9700000000-d475fd0478daf18a419a
LC-MS/MS Spectrum - LC-ESI-QFT , negativeLC-MS/MSsplash10-0006-9100000000-3daaf3c8697e17e67869
LC-MS/MS Spectrum - LC-ESI-QFT , negativeLC-MS/MSsplash10-0006-9000000000-ee876bcdd1a5c7c229a0
LC-MS/MS Spectrum - LC-ESI-QFT , negativeLC-MS/MSsplash10-0006-9000000000-cd4e1f8fe0a2bbc869f9
LC-MS/MS Spectrum - LC-ESI-QFT , negativeLC-MS/MSsplash10-0006-9000000000-4dca49851b5b9fd03d1a
LC-MS/MS Spectrum - LC-ESI-QFT , negativeLC-MS/MSsplash10-00kf-9000000000-4611655c6aff89d706eb
LC-MS/MS Spectrum - LC-ESI-QFT , negativeLC-MS/MSsplash10-014l-9000000000-4d636e2d7318b857528d
LC-MS/MS Spectrum - LC-ESI-QFT , positiveLC-MS/MSsplash10-01ot-0900000000-1256ca04e4244fbc4a64
LC-MS/MS Spectrum - LC-ESI-QFT , positiveLC-MS/MSsplash10-01ot-0900000000-2cae7e19320bfa1a03a0
LC-MS/MS Spectrum - LC-ESI-QFT , positiveLC-MS/MSsplash10-01ot-0900000000-42f69c49b256900b7524
LC-MS/MS Spectrum - LC-ESI-QFT , positiveLC-MS/MSsplash10-01ot-0900000000-4860d5cbeeb9c31311ec
LC-MS/MS Spectrum - LC-ESI-QFT , positiveLC-MS/MSsplash10-006t-3900000000-cc185048e2a1bcc52124
LC-MS/MS Spectrum - LC-ESI-QFT , positiveLC-MS/MSsplash10-01ba-9700000000-ec436cb71e803899f611
LC-MS/MS Spectrum - LC-ESI-QFT , positiveLC-MS/MSsplash10-014i-9100000000-75f611f9e761b63033d9
LC-MS/MS Spectrum - LC-ESI-QFT , positiveLC-MS/MSsplash10-02tc-9000000000-15b9abe0f191aedd9620
LC-MS/MS Spectrum - LC-ESI-QFT , positiveLC-MS/MSsplash10-0ik9-9000000000-644d508a79eb48c24ec3
1H NMR Spectrum1D NMRNot Applicable
1H NMR Spectrum1D NMRNot Applicable
13C NMR Spectrum1D NMRNot Applicable
[1H,13C] 2D NMR Spectrum2D NMRNot Applicable

Taxonomy

Description
This compound belongs to the class of organic compounds known as acylsalicylic acids. These are o-acylated derivatives of salicylic acid.
Kingdom
Organic compounds
Super Class
Benzenoids
Class
Benzene and substituted derivatives
Sub Class
Benzoic acids and derivatives
Direct Parent
Acylsalicylic acids
Alternative Parents
Phenol esters / Benzoic acids / Phenoxy compounds / Benzoyl derivatives / Dicarboxylic acids and derivatives / Carboxylic acid esters / Carboxylic acids / Organic oxides / Hydrocarbon derivatives / Carbonyl compounds
Substituents
Acylsalicylic acid / Phenol ester / Benzoic acid / Phenoxy compound / Benzoyl / Dicarboxylic acid or derivatives / Carboxylic acid ester / Carboxylic acid / Carboxylic acid derivative / Organic oxygen compound
Molecular Framework
Aromatic homomonocyclic compounds
External Descriptors
salicylates, acetate ester, benzoic acids (CHEBI:15365)

Targets

Kind
Protein
Organism
Human
Pharmacological action
Yes
Actions
Inhibitor
General Function
Prostaglandin-endoperoxide synthase activity
Specific Function
Converts arachidonate to prostaglandin H2 (PGH2), a committed step in prostanoid synthesis. Involved in the constitutive production of prostanoids in particular in the stomach and platelets. In gas...
Gene Name
PTGS1
Uniprot ID
P23219
Uniprot Name
Prostaglandin G/H synthase 1
Molecular Weight
68685.82 Da
References
  1. Stevenson DD, Szczeklik A: Clinical and pathologic perspectives on aspirin sensitivity and asthma. J Allergy Clin Immunol. 2006 Oct;118(4):773-86; quiz 787-8. Epub 2006 Sep 1. [PubMed:17030227]
  2. Flipo RM: [Are the NSAIDs able to compromising the cardio-preventive efficacy of aspirin?]. Presse Med. 2006 Sep;35(9 Spec No 1):1S53-60. [PubMed:17078596]
  3. Schwartz KA: Aspirin resistance: a review of diagnostic methodology, mechanisms, and clinical utility. Adv Clin Chem. 2006;42:81-110. [PubMed:17131625]
  4. Birnbaum Y, Ye Y, Lin Y, Freeberg SY, Huang MH, Perez-Polo JR, Uretsky BF: Aspirin augments 15-epi-lipoxin A4 production by lipopolysaccharide, but blocks the pioglitazone and atorvastatin induction of 15-epi-lipoxin A4 in the rat heart. Prostaglandins Other Lipid Mediat. 2007 Feb;83(1-2):89-98. Epub 2006 Nov 7. [PubMed:17259075]
  5. Guthikonda S, Lev EI, Patel R, DeLao T, Bergeron AL, Dong JF, Kleiman NS: Reticulated platelets and uninhibited COX-1 and COX-2 decrease the antiplatelet effects of aspirin. J Thromb Haemost. 2007 Mar;5(3):490-6. [PubMed:17319904]
  6. Chen X, Ji ZL, Chen YZ: TTD: Therapeutic Target Database. Nucleic Acids Res. 2002 Jan 1;30(1):412-5. [PubMed:11752352]
Kind
Protein
Organism
Human
Pharmacological action
Yes
Actions
Inhibitor
General Function
Prostaglandin-endoperoxide synthase activity
Specific Function
Converts arachidonate to prostaglandin H2 (PGH2), a committed step in prostanoid synthesis. Constitutively expressed in some tissues in physiological conditions, such as the endothelium, kidney and...
Gene Name
PTGS2
Uniprot ID
P35354
Uniprot Name
Prostaglandin G/H synthase 2
Molecular Weight
68995.625 Da
References
  1. Brzozowski T, Konturek PC, Sliwowski Z, Kwiecien S, Drozdowicz D, Pawlik M, Mach K, Konturek SJ, Pawlik WW: Interaction of nonsteroidal anti-inflammatory drugs (NSAID) with Helicobacter pylori in the stomach of humans and experimental animals. J Physiol Pharmacol. 2006 Sep;57 Suppl 3:67-79. [PubMed:17033106]
  2. Wang HJ, Liu XJ, Yang KX, Luo FM, Lou JY, Peng ZL: [Effects of nonsteroidal anti-inflammatory drug celecoxib on expression of cyclooxygenase-2 (COX-2) in ovarian carcinoma cell]. Sichuan Da Xue Xue Bao Yi Xue Ban. 2006 Sep;37(5):757-60. [PubMed:17037745]
  3. Shen J, Gammon MD, Terry MB, Teitelbaum SL, Neugut AI, Santella RM: Genetic polymorphisms in the cyclooxygenase-2 gene, use of nonsteroidal anti-inflammatory drugs, and breast cancer risk. Breast Cancer Res. 2006;8(6):R71. [PubMed:17181859]
  4. Nakano M, Denda N, Matsumoto M, Kawamura M, Kawakubo Y, Hatanaka K, Hiramoto Y, Sato Y, Noshiro M, Harada Y: Interaction between cyclooxygenase (COX)-1- and COX-2-products modulates COX-2 expression in the late phase of acute inflammation. Eur J Pharmacol. 2007 Mar 22;559(2-3):210-8. Epub 2006 Dec 16. [PubMed:17258197]
  5. Hall MN, Campos H, Li H, Sesso HD, Stampfer MJ, Willett WC, Ma J: Blood levels of long-chain polyunsaturated fatty acids, aspirin, and the risk of colorectal cancer. Cancer Epidemiol Biomarkers Prev. 2007 Feb;16(2):314-21. [PubMed:17301265]
  6. Chen X, Ji ZL, Chen YZ: TTD: Therapeutic Target Database. Nucleic Acids Res. 2002 Jan 1;30(1):412-5. [PubMed:11752352]
Kind
Protein
Organism
Human
Pharmacological action
Unknown
Actions
Inhibitor
General Function
Trans-1,2-dihydrobenzene-1,2-diol dehydrogenase activity
Specific Function
Converts progesterone to its inactive form, 20-alpha-dihydroxyprogesterone (20-alpha-OHP). In the liver and intestine, may have a role in the transport of bile. May have a role in monitoring the in...
Gene Name
AKR1C1
Uniprot ID
Q04828
Uniprot Name
Aldo-keto reductase family 1 member C1
Molecular Weight
36788.02 Da
References
  1. Dhagat U, Carbone V, Chung RP, Matsunaga T, Endo S, Hara A, El-Kabbani O: A salicylic acid-based analogue discovered from virtual screening as a potent inhibitor of human 20alpha-hydroxysteroid dehydrogenase. Med Chem. 2007 Nov;3(6):546-50. [PubMed:18045204]
Kind
Protein
Organism
Human
Pharmacological action
Unknown
Actions
Activator
General Function
Tau-protein kinase activity
Specific Function
Catalytic subunit of AMP-activated protein kinase (AMPK), an energy sensor protein kinase that plays a key role in regulating cellular energy metabolism. In response to reduction of intracellular A...
Gene Name
PRKAA1
Uniprot ID
Q13131
Uniprot Name
5'-AMP-activated protein kinase catalytic subunit alpha-1
Molecular Weight
64008.64 Da
References
  1. Din FV, Valanciute A, Houde VP, Zibrova D, Green KA, Sakamoto K, Alessi DR, Dunlop MG: Aspirin inhibits mTOR signaling, activates AMP-activated protein kinase, and induces autophagy in colorectal cancer cells. Gastroenterology. 2012 Jun;142(7):1504-15.e3. doi: 10.1053/j.gastro.2012.02.050. Epub 2012 Mar 6. [PubMed:22406476]
  2. Hawley SA, Fullerton MD, Ross FA, Schertzer JD, Chevtzoff C, Walker KJ, Peggie MW, Zibrova D, Green KA, Mustard KJ, Kemp BE, Sakamoto K, Steinberg GR, Hardie DG: The ancient drug salicylate directly activates AMP-activated protein kinase. Science. 2012 May 18;336(6083):918-22. doi: 10.1126/science.1215327. Epub 2012 Apr 19. [PubMed:22517326]
Kind
Protein
Organism
Human
Pharmacological action
Unknown
Actions
Inhibitor
General Function
Phosphatidylinositol phospholipase c activity
Specific Function
Receptor for endothelin-1. Mediates its action by association with G proteins that activate a phosphatidylinositol-calcium second messenger system. The rank order of binding affinities for ET-A is:...
Gene Name
EDNRA
Uniprot ID
P25101
Uniprot Name
Endothelin-1 receptor
Molecular Weight
48721.76 Da
References
  1. Talbodec A, Berkane N, Blandin V, Breittmayer JP, Ferrari E, Frelin C, Vigne P: Aspirin and sodium salicylate inhibit endothelin ETA receptors by an allosteric type of mechanism. Mol Pharmacol. 2000 Apr;57(4):797-804. [PubMed:10727528]
Kind
Protein
Organism
Human
Pharmacological action
Unknown
Actions
Inhibitor
General Function
Scaffold protein binding
Specific Function
Serine kinase that plays an essential role in the NF-kappa-B signaling pathway which is activated by multiple stimuli such as inflammatory cytokines, bacterial or viral products, DNA damages or oth...
Gene Name
IKBKB
Uniprot ID
O14920
Uniprot Name
Inhibitor of nuclear factor kappa-B kinase subunit beta
Molecular Weight
86563.245 Da
References
  1. Yin MJ, Yamamoto Y, Gaynor RB: The anti-inflammatory agents aspirin and salicylate inhibit the activity of I(kappa)B kinase-beta. Nature. 1998 Nov 5;396(6706):77-80. [PubMed:9817203]
Kind
Protein
Organism
Human
Pharmacological action
Unknown
Actions
Acetylation
General Function
Not Available
Specific Function
Not Available
Gene Name
TP53
Uniprot ID
P04637
Uniprot Name
Cellular tumor antigen p53
Molecular Weight
43652.79 Da
References
  1. Alfonso LF, Srivenugopal KS, Bhat GJ: Does aspirin acetylate multiple cellular proteins? (Review). Mol Med Rep. 2009 Jul-Aug;2(4):533-7. doi: 10.3892/mmr_00000132. [PubMed:21475861]
Kind
Protein
Organism
Human
Pharmacological action
Unknown
Actions
Binding
General Function
Unfolded protein binding
Specific Function
Probably plays a role in facilitating the assembly of multimeric protein complexes inside the endoplasmic reticulum. Involved in the correct folding of proteins and degradation of misfolded protein...
Gene Name
HSPA5
Uniprot ID
P11021
Uniprot Name
78 kDa glucose-regulated protein
Molecular Weight
72332.425 Da
References
  1. Deng WG, Ruan KH, Du M, Saunders MA, Wu KK: Aspirin and salicylate bind to immunoglobulin heavy chain binding protein (BiP) and inhibit its ATPase activity in human fibroblasts. FASEB J. 2001 Nov;15(13):2463-70. [PubMed:11689471]
Kind
Protein
Organism
Human
Pharmacological action
Unknown
Actions
Inhibitor
General Function
Ribosomal protein s6 kinase activity
Specific Function
Serine/threonine-protein kinase that acts downstream of ERK (MAPK1/ERK2 and MAPK3/ERK1) signaling and mediates mitogenic and stress-induced activation of the transcription factors CREB1, ETV1/ER81 ...
Gene Name
RPS6KA3
Uniprot ID
P51812
Uniprot Name
Ribosomal protein S6 kinase alpha-3
Molecular Weight
83735.325 Da
References
  1. Stevenson MA, Zhao MJ, Asea A, Coleman CN, Calderwood SK: Salicylic acid and aspirin inhibit the activity of RSK2 kinase and repress RSK2-dependent transcription of cyclic AMP response element binding protein- and NF-kappa B-responsive genes. J Immunol. 1999 Nov 15;163(10):5608-16. [PubMed:10553090]
Kind
Protein
Organism
Human
Pharmacological action
Unknown
Actions
Inhibitor
General Function
Ubiquitin protein ligase binding
Specific Function
Inhibits the activity of dimeric NF-kappa-B/REL complexes by trapping REL dimers in the cytoplasm through masking of their nuclear localization signals. On cellular stimulation by immune and proinf...
Gene Name
NFKBIA
Uniprot ID
P25963
Uniprot Name
NF-kappa-B inhibitor alpha
Molecular Weight
35608.65 Da
References
  1. Stevenson MA, Zhao MJ, Asea A, Coleman CN, Calderwood SK: Salicylic acid and aspirin inhibit the activity of RSK2 kinase and repress RSK2-dependent transcription of cyclic AMP response element binding protein- and NF-kappa B-responsive genes. J Immunol. 1999 Nov 15;163(10):5608-16. [PubMed:10553090]
Kind
Protein
Organism
Human
Pharmacological action
Unknown
Actions
Antagonist
General Function
Transcriptional activator activity, rna polymerase ii core promoter proximal region sequence-specific binding
Specific Function
NF-kappa-B is a pleiotropic transcription factor present in almost all cell types and is the endpoint of a series of signal transduction events that are initiated by a vast array of stimuli related...
Gene Name
NFKB2
Uniprot ID
Q00653
Uniprot Name
Nuclear factor NF-kappa-B p100 subunit
Molecular Weight
96748.355 Da
References
  1. Kopp E, Ghosh S: Inhibition of NF-kappa B by sodium salicylate and aspirin. Science. 1994 Aug 12;265(5174):956-9. [PubMed:8052854]

Enzymes

Kind
Protein
Organism
Human
Pharmacological action
Unknown
Actions
Inducer
General Function
Steroid hydroxylase activity
Specific Function
Responsible for the metabolism of a number of therapeutic agents such as the anticonvulsant drug S-mephenytoin, omeprazole, proguanil, certain barbiturates, diazepam, propranolol, citalopram and im...
Gene Name
CYP2C19
Uniprot ID
P33261
Uniprot Name
Cytochrome P450 2C19
Molecular Weight
55930.545 Da
References
  1. Preissner S, Kroll K, Dunkel M, Senger C, Goldsobel G, Kuzman D, Guenther S, Winnenburg R, Schroeder M, Preissner R: SuperCYP: a comprehensive database on Cytochrome P450 enzymes including a tool for analysis of CYP-drug interactions. Nucleic Acids Res. 2010 Jan;38(Database issue):D237-43. doi: 10.1093/nar/gkp970. Epub 2009 Nov 24. [PubMed:19934256]
Kind
Protein
Organism
Human
Pharmacological action
Unknown
Actions
Substrate
General Function
Steroid hydroxylase activity
Specific Function
Cytochromes P450 are a group of heme-thiolate monooxygenases. In liver microsomes, this enzyme is involved in an NADPH-dependent electron transport pathway. It oxidizes a variety of structurally un...
Gene Name
CYP2C8
Uniprot ID
P10632
Uniprot Name
Cytochrome P450 2C8
Molecular Weight
55824.275 Da
References
  1. Preissner S, Kroll K, Dunkel M, Senger C, Goldsobel G, Kuzman D, Guenther S, Winnenburg R, Schroeder M, Preissner R: SuperCYP: a comprehensive database on Cytochrome P450 enzymes including a tool for analysis of CYP-drug interactions. Nucleic Acids Res. 2010 Jan;38(Database issue):D237-43. doi: 10.1093/nar/gkp970. Epub 2009 Nov 24. [PubMed:19934256]
Kind
Protein
Organism
Human
Pharmacological action
Unknown
Actions
Substrate
General Function
Steroid hydroxylase activity
Specific Function
Cytochromes P450 are a group of heme-thiolate monooxygenases. In liver microsomes, this enzyme is involved in an NADPH-dependent electron transport pathway. It oxidizes a variety of structurally un...
Gene Name
CYP2C9
Uniprot ID
P11712
Uniprot Name
Cytochrome P450 2C9
Molecular Weight
55627.365 Da
References
  1. Preissner S, Kroll K, Dunkel M, Senger C, Goldsobel G, Kuzman D, Guenther S, Winnenburg R, Schroeder M, Preissner R: SuperCYP: a comprehensive database on Cytochrome P450 enzymes including a tool for analysis of CYP-drug interactions. Nucleic Acids Res. 2010 Jan;38(Database issue):D237-43. doi: 10.1093/nar/gkp970. Epub 2009 Nov 24. [PubMed:19934256]

Carriers

Kind
Protein
Organism
Human
Pharmacological action
No
Actions
Other/unknown
General Function
Toxic substance binding
Specific Function
Serum albumin, the main protein of plasma, has a good binding capacity for water, Ca(2+), Na(+), K(+), fatty acids, hormones, bilirubin and drugs. Its main function is the regulation of the colloid...
Gene Name
ALB
Uniprot ID
P02768
Uniprot Name
Serum albumin
Molecular Weight
69365.94 Da
References
  1. Sulkowska A, Bojko B, Rownicka J, Sulkowski WW: Competition of cytarabine and aspirin in binding to serum albumin in multidrug therapy. Biopolymers. 2006 Apr 15;81(6):464-72. [PubMed:16419075]
  2. Dundee JW, Halliday NJ, McMurray TJ: Aspirin and probenecid pretreatment influences the potency of thiopentone and the onset of action of midazolam. Eur J Anaesthesiol. 1986 May;3(3):247-51. [PubMed:3780693]

Transporters

Kind
Protein
Organism
Human
Pharmacological action
Unknown
Actions
Inhibitor
General Function
Sodium-independent organic anion transmembrane transporter activity
Specific Function
Involved in the renal elimination of endogenous and exogenous organic anions. Functions as organic anion exchanger when the uptake of one molecule of organic anion is coupled with an efflux of one ...
Gene Name
SLC22A6
Uniprot ID
Q4U2R8
Uniprot Name
Solute carrier family 22 member 6
Molecular Weight
61815.78 Da
References
  1. Apiwattanakul N, Sekine T, Chairoungdua A, Kanai Y, Nakajima N, Sophasan S, Endou H: Transport properties of nonsteroidal anti-inflammatory drugs by organic anion transporter 1 expressed in Xenopus laevis oocytes. Mol Pharmacol. 1999 May;55(5):847-54. [PubMed:10220563]
Kind
Protein
Organism
Human
Pharmacological action
Unknown
Actions
Substrate
General Function
Xenobiotic-transporting atpase activity
Specific Function
Energy-dependent efflux pump responsible for decreased drug accumulation in multidrug-resistant cells.
Gene Name
ABCB1
Uniprot ID
P08183
Uniprot Name
Multidrug resistance protein 1
Molecular Weight
141477.255 Da
References
  1. Faassen F, Vogel G, Spanings H, Vromans H: Caco-2 permeability, P-glycoprotein transport ratios and brain penetration of heterocyclic drugs. Int J Pharm. 2003 Sep 16;263(1-2):113-22. [PubMed:12954186]
Kind
Protein
Organism
Human
Pharmacological action
Unknown
Actions
Substrate
General Function
Sodium-independent organic anion transmembrane transporter activity
Specific Function
Mediates sodium-independent multispecific organic anion transport. Transport of prostaglandin E2, prostaglandin F2, tetracycline, bumetanide, estrone sulfate, glutarate, dehydroepiandrosterone sulf...
Gene Name
SLC22A7
Uniprot ID
Q9Y694
Uniprot Name
Solute carrier family 22 member 7
Molecular Weight
60025.025 Da
References
  1. Sekine T, Cha SH, Tsuda M, Apiwattanakul N, Nakajima N, Kanai Y, Endou H: Identification of multispecific organic anion transporter 2 expressed predominantly in the liver. FEBS Lett. 1998 Jun 12;429(2):179-82. [PubMed:9650585]

Drug created on June 13, 2005 07:24 / Updated on June 24, 2018 11:36